WO2010050554A1 - ヒトcxcl1タンパク質の免疫学的測定方法 - Google Patents
ヒトcxcl1タンパク質の免疫学的測定方法 Download PDFInfo
- Publication number
- WO2010050554A1 WO2010050554A1 PCT/JP2009/068587 JP2009068587W WO2010050554A1 WO 2010050554 A1 WO2010050554 A1 WO 2010050554A1 JP 2009068587 W JP2009068587 W JP 2009068587W WO 2010050554 A1 WO2010050554 A1 WO 2010050554A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino acid
- seq
- acid sequence
- human cxcl1
- antibody
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
Definitions
- the present invention relates to a method for measuring human CXCL1 protein (hereinafter referred to as human CXCL1). More specifically, it is a method for measuring human CXCL1, which is an immunization combining a monoclonal antibody or a fragment thereof that specifically binds to any of three specific partial sequence regions on the amino acid sequence constituting human CXCL1.
- the present invention relates to a measurement method.
- the present invention also relates to a monoclonal antibody that specifically binds to human CXCL1, or a fragment thereof, which can be used in the aforementioned method for measuring human CXCL1 protein.
- Human CXCL1 is a type of chemokine belonging to the CXC family. This protein is present in platelets in blood and is known to be overexpressed during an inflammatory reaction like other CXC families.
- Non-patent Document 1 a tumor-related factor. Therefore, it is expected that it can be a marker for urothelial cancer by quantitative detection from urine.
- Non-patent Document 1 Patent Document 1
- human CXCL1 has been reported to vary at the gene level and protein level in tissues and blood of patients with other malignant tumors such as colorectal cancer, ovarian cancer, and malignant melanoma
- Non-Patent Document 2, Non-patent Document 2, Patent Document 3 and Non-Patent Document 4 have potential to detect not only urothelial cancer but also these cancers very early and / or early.
- the measurement method using the existing enzyme immunoassay lacks the sensitivity necessary to detect the cancer.
- the human CXCL1 measurement kit manufactured by R & D SYSTEMS (hereinafter referred to as R & D SYSTEMS) described in Patent Document 1 has a detection limit concentration of about 20 pg / mL, whereas the human CXCL1 concentration in normal human urine is detected. Less than the limit. Therefore, a more sensitive method for measuring human CXCL1 has been desired.
- an object of one embodiment of the present invention is to provide an immunological measurement method for detecting human CXCL1 with higher sensitivity. More specifically, human CXCL1 is further expressed by an immunoassay that combines an antibody or antigen recognition portion that specifically binds to any one of the three specific sequences of the amino acid sequence constituting human CXCL1. The object is to realize a method of detecting with high sensitivity.
- Another object of the present invention is to provide a monoclonal antibody that specifically recognizes human CXCL1 or a fragment thereof. More specifically, it includes a novel amino acid sequence that specifically recognizes human CXCL1 and can be used in the aforementioned method for detecting human CXCL1 with higher sensitivity, and has a higher affinity than conventional antibodies. Another object is to provide antibodies or fragments thereof.
- the present inventors have recognized monoclonal antibodies or antigens that specifically bind to three specific partial sequence regions of the amino acid sequence constituting human CXCL1. It has been found that human CXCL1 can be detected with higher sensitivity than before by combining the portions and measuring immunologically.
- a monoclonal antibody containing a novel amino acid sequence that specifically binds to three partial sequences on the above-mentioned human CXCL1 and a hybridoma producing the antibody were successfully produced.
- a gene encoding the amino acid sequence constituting the antibody was isolated and its base sequence was determined. This made it possible to produce recombinant antibodies and their recombinant fragments. This invention is made
- a human CXCL1 protein or a fragment thereof in a sample is measured using an anti-human CXCL1 monoclonal antibody that specifically recognizes the amino acid sequence region represented by SEQ ID NO: 3 or a fragment thereof.
- the immunological measurement method for human CXCL1 protein according to 1).
- An anti-human CXCL1 monoclonal antibody or a fragment thereof, which comprises the amino acid sequence represented by SEQ ID NO: 24 and CDR3 comprises the amino acid sequence represented by SEQ ID NO: 25.
- the concentration of human CXCL1 can be measured with higher sensitivity than before.
- a high-affinity anti-human CXCL1 monoclonal antibody that specifically recognizes human CXCL1 or a fragment thereof can be provided.
- a commercially available antibody that specifically recognizes the amino acid sequence represented by SEQ ID NO: 2 is immobilized on a solid phase, and the biotinylated labeled antibody of the present invention that recognizes the amino acid sequence represented by SEQ ID NO: 3 or a commercially available biotin-labeled anti-human CXCL1 polyclonal antibody
- Sandwich ELISA method using 5 types of antibodies of the present invention (IgG1-1, IgG1-3, IgG1-10, IgG1-14, IgG2b-1) and commercially available antibodies, and using biotin-labeled anti-human CXCL1 polyclonal antibody
- the graph which detected human CXCL1 in a buffer solution by FIG. 5 is a graph in which human CXCL1 in plasma is detected by sandwich ELISA using five antibodies of the present invention and a commercially available antibody immobilized on a solid phase and a biotin-labeled anti-human CXCL1 polyclonal antibody.
- FIG. 5 is a graph in which human CXCL1 in urine is detected by sandwich ELISA using five types of antibodies of the present invention and a commercially available antibody, and a biotin-labeled anti-human CXCL1 polyclonal antibody.
- the graph (1) which showed the bladder cancer cell infiltration suppression ability of five types of antibodies of this invention, and a commercially available antibody.
- the graph (2) which showed the bladder cancer cell infiltration suppression ability of four types of antibodies of this invention, and a commercially available antibody.
- human CXCL1 means a protein consisting of the amino acid sequence described in Genbank NM — 001511 or a natural variant thereof.
- natural variant refers to a variant that exists in nature, for example, one in which one or several amino acids are deleted, substituted, or added in the amino acid sequence, It has 95% or more, preferably 98% or more, more preferably 99% or more.
- identity includes the number of gaps when two amino acid sequences are aligned (aligned) with or without introducing gaps between the two amino acid sequences.
- “Several” means an integer of 2 to 10, for example, an integer of 2 to 7, 2 to 5, 2 to 4, 2 to 3.
- Specific examples of natural mutants include mutants based on polymorphisms such as SNP (single nucleotide polymorphism), splice mutants, and the like.
- the substitution is preferably a conservative amino acid substitution. This is because a conservative amino acid substitution may have a structure or property substantially equivalent to human CXCL1 having the amino acid sequence.
- Conservative amino acids include nonpolar amino acids (glycine, alanine, phenylalanine, valine, leucine, isoleucine, methionine, proline, tryptophan), polar amino acids (amino acids other than nonpolar amino acids), charged amino acids (acidic amino acids (aspartic acid) , Glutamic acid) and basic amino acids (arginine, histidine, lysine)) and uncharged amino acids (amino acids other than charged amino acids), aromatic amino acids (phenylalanine, tryptophan, tyrosine), branched amino acids (leucine, isoleucine, valine), and Aliphatic amino acids (glycine, alanine, leucine, isoleucine, valine) and the like are known.
- “monoclonal antibody” includes a framework region (FR) derived from an immunoglobulin or a fragment thereof and a complementary chain determining region (CDR) and is specific to an antigen.
- FR framework region
- CDR complementary chain determining region
- the “anti-human CXCL1 monoclonal antibody” of the present invention refers to a polypeptide that specifically binds to human CXCL1 or a fragment thereof and can recognize human CXCL1 or a fragment thereof.
- Specific binding means binding only to a target antigen (human CXCL1 or a fragment thereof in the present invention).
- a typical immunoglobulin molecule is constructed as a tetramer in which two sets of polypeptide chains, called heavy and light chains, are interconnected in two pairs by disulfide bonds.
- the heavy chain consists of an N-terminal heavy chain variable region (V H ) and a C-terminal heavy chain constant region (C H )
- the light chain consists of an N-terminal light chain variable region (V L ) and C It consists of the terminal light chain constant region (C L ).
- V H and V L are particularly important in that they are involved in antibody binding specificity.
- Each of V H and V L is composed of about 110 amino acid residues, and has three complementarity determining regions (CDR1, CDR2, CDR3) directly involved in the binding specificity to an antigen therein, and a variable region. It has four framework regions (FR1, FR2, FR3, FR4) that function as the skeleton structure.
- the complementary chain determining region is known to form a three-dimensional structure complementary to the antigen molecule and determine the specificity of the antibody (EA Kabat et al, 1991, Sequences of proteins of immunological interest, Vol. .1, eds.5, NIH publication).
- the amino acid sequence of the constant region is almost unchanged between intraspecific antibodies, whereas the amino acid sequence of the complementary chain determining region is highly variable between antibodies, and is therefore also called a hypervariable region. .
- the complementarity determining region and the framework region are arranged in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino acid end to the carboxy terminal direction.
- V L and V H form an antigen binding site by forming a dimer relative to each other in the immunoglobulin molecule.
- immunoglobulins IgG, IgM, IgA, IgE, and IgD classes are known, but the antibody of the present invention may be any class. IgG is preferred.
- Antibodies useful in the present invention can be derived from any animal source including birds and mammals. Examples include mice, rats, guinea pigs, rabbits, goats, donkeys, sheep, camels, horses, chickens, and humans.
- the “monoclonal antibody” of the present invention may be synthesized chemically or by using a recombinant DNA method. For example, chimeric antibodies and recombinant antibodies such as humanized antibodies are also included in the present invention.
- a chimeric antibody is an antibody in which the constant region of one antibody is replaced with the constant region of another antibody.
- an antibody in which the constant region is replaced with the constant region of a human antibody is applicable.
- V L comprises the amino acid sequence in the V L of anti-human CXCL1 mouse monoclonal antibody shown in any of SEQ ID NO: 10,18,26,34, or 42
- C L is any comprises an amino acid sequence at the C L of a human antibody
- V H comprises the amino acid sequence of V H of anti-human CXCL1 mouse monoclonal antibody shown in any of SEQ ID NO: 11,19,27,35, or 43
- an antibody in which C H contains an amino acid sequence in C H of any human antibody is
- a humanized antibody is a mosaic antibody in which CDR groups derived from a certain antibody (usually a non-human antibody such as a mouse antibody) are artificially combined with the FR and constant region of a human antibody.
- CDR groups derived from a certain antibody usually a non-human antibody such as a mouse antibody
- an antibody combining each CDR of an anti-human CXCL1 mouse monoclonal antibody, each FR of an arbitrary human antibody, and a constant region is applicable. Since the antigen-binding specificity of an antibody is mainly borne by the CDRs in the variable region, the entire amino acid sequence of a certain antibody is obtained when producing a recombinant antibody having the same binding characteristics as that of the certain antibody. There is no need.
- a mosaic antibody is prepared by replacing a DNA sequence encoding each CDR derived from a certain antibody with a DNA sequence encoding a corresponding CDR derived from a human antibody, and expressing it.
- a recombinant antibody that mimics the properties of a certain antibody can be obtained.
- Such a technique is called a CDR grafted antibody. Nature, 1986, Vol. 321, 522.
- the anti-human CXCL1 antibody or fragment thereof of the present invention does not necessarily need to be a humanized antibody when used for detection of human CXCL1 or a fragment thereof. Can be derived from antibodies of any animal other than human.
- the “antibody” may be a multispecific antibody.
- a multispecific antibody refers to a multivalent antibody, that is, an antibody that binds to different epitopes in each antigen-binding site in an antibody having a plurality of antigen-binding sites in one molecule.
- a bispecific antibody in which each antigen binding site binds to a different epitope can be mentioned.
- the multispecific antibody is preferably capable of binding to different epitopes in which each antigen-binding site is present on human CXCL1. These antibodies can be obtained by artificially modifying IgG or the like by a known method using recombinant DNA technology.
- a fragment thereof in “monoclonal antibody or fragment thereof” is a partial region of the antibody, and has substantially the same activity as the antigen-specific binding activity of the antibody.
- a polypeptide chain or a complex thereof is applicable.
- Specific examples include a number of well-characterized antibody fragments generated by cleaving immunoglobulins with various peptidases. More specific examples include Fab, F (ab ′) 2 , Fab ′ and the like.
- Fab is a fragment caused by IgG molecule by papain is cleaved at the N-terminal side of the disulfide linkages in the hinge portion, the three domains that make up the V H and C H (C H 1, C H 2, C H 3) is composed of a polypeptide consisting of C H 1 adjacent to V H and a light chain.
- F (ab ′) 2 is a dimer of Fab ′ produced by cleaving IgG molecules at the C-terminal side of the disulfide bond at the hinge part by pepsin.
- Fab ′ is slightly longer in H chain than the Fab, but has a structure substantially equivalent to that of Fab (Fundamental Immunology, Paul ed., 3d ed., 1993).
- Fab ′ can be obtained by reducing F (ab ′) 2 under mild conditions and breaking the disulfide linkage in the hinge region.
- Each of these antibody fragments includes an antigen-binding site and has an ability to specifically bind to an antigen (that is, human CXCL1 or a fragment thereof in the present invention).
- the “fragment thereof” of the present invention may be synthesized chemically or by using a recombinant DNA method.
- an antibody fragment newly synthesized using a recombinant DNA method can be mentioned.
- Ichiryou body obtained by artificially linked via a linker peptide or the like having one or more V L and one or more V H appropriate length and sequence of the antibody of the present invention It corresponds to a polypeptide molecule or a multimeric polypeptide thereof.
- Examples of such polypeptides include single chain Fv (scFv: single chain Fragment of variable region) (Pierce catalog and Handbook, 1994-1995, Pierce Chemical co., Rockford, IL di) (see Body, Diab).
- VL and VH are usually located on separate polypeptide chains (light chain and heavy chain).
- a single chain Fv is a synthetic antibody fragment in which these variable regions are connected by a flexible linker having a sufficient length and has a structure encompassed by a single polypeptide chain. Within the single chain Fv, both variable regions can self-assemble with each other to form one functional antigen binding site.
- Single-stranded Fv can be obtained by integrating and expressing a recombinant DNA encoding the same into a phage genome using known techniques.
- a diabody is a molecule having a structure based on a dimeric structure of a single chain Fv (Holliger et al, 1993, Proc. Natl. Acad. Sci USA, 90: 6444-6448).
- the linker is shorter than about 12 amino acid residues, the two variable sites within the single chain Fv cannot self-assemble, but by forming a diabody, ie, two single chain Fv Can interact with the V L of one Fv chain and the V H of the other Fv chain to form two functional antigen binding sites (Marvin et al, 2005, Acta Pharmacol). Sin., 26: 649-658).
- a diabody is a bivalent antibody fragment, but each antigen-binding site need not bind to the same epitope, and each has a bispecificity that recognizes and specifically binds to a different epitope. It does not matter.
- one antigen-binding site is represented by SEQ ID NOs: 39, 40, and 41 including a VL containing CDRs (corresponding to CDR1, CDR2, and CDR3, respectively) containing the amino acid sequences represented by SEQ ID NOs: 36, 37, and 38.
- CDR comprising an amino acid sequence (respectively, CDRl, CDR2, CDR3 correspond to) a V H containing, other antigen-binding sites
- CDR comprising an amino acid sequence represented by SEQ ID NO: 28, 29, 30
- CDRl, CDR2, CDR comprising an amino acid sequence represented by V L and SEQ ID NO: 31, 32, 33 including the corresponding to CDR3
- CDRl, CDR2, corresponding to CDR3 may consist V H containing.
- Triabodies and tetrabodies have their trimer and tetramer structures based on a single-chain Fv structure as in the diabody. These are trivalent and tetravalent antibody fragments, respectively, and may be multispecific antibodies.
- fragment thereof is an antibody fragment identified using a phage display library (see, for example, McCafferty et al., 1990, Nature, Vol. 348, 522-554) and has an antigen-binding ability.
- a phage display library see, for example, McCafferty et al., 1990, Nature, Vol. 348, 522-554
- has an antigen-binding ability are included.
- Kuby, J. et al. Immunology, 3rd Ed. 1998, W.M. H. Freeman & Co. See also New York.
- the present invention provides an antibody or a fragment thereof having a variable region having a desirable binding activity for human CXCL1, and an amino acid sequence constituting the CDR. That is, the present invention provides an antibody or fragment thereof comprising an immunoglobulin variable region comprising the amino acid sequence shown in any of SEQ ID NOs: 4 to 43.
- the antibody of the present invention or a fragment thereof includes the amino acid sequences represented by SEQ ID NOs: 4, 5, and 6 in the light chain of CDR1, CDR2, and CDR3, respectively, and the CDR1, CDR2, and CDR3 of SEQ ID NO: in the heavy chain thereof, respectively.
- the amino acid sequence shown by 7, 8, 9 can be included.
- V L and V H can include the amino acid sequences represented by SEQ ID NO: 10 and SEQ ID NO: 11, respectively.
- the antibody of the present invention or a fragment thereof includes the amino acid sequences represented by SEQ ID NOs: 12, 13, and 14 in the light chain of the CDR1, CDR2, and CDR3, respectively, and the CDR1, CDR2, and CDR3 of the heavy chain in the SEQ ID NO:
- the amino acid sequence shown by 15, 16, 17 can be included.
- V L and V H can include the amino acid sequences represented by SEQ ID NO: 18 and SEQ ID NO: 19, respectively.
- the antibody of the present invention or a fragment thereof includes the amino acid sequences represented by SEQ ID NOs: 20, 21, and 22 in the light chain of the CDR1, CDR2, and CDR3, respectively, and CDR1, CDR2, and CDR3 of the heavy chain in the light chain.
- the amino acid sequence shown by 23, 24, 25 can be included.
- V L and V H can include the amino acid sequences represented by SEQ ID NO: 26 and SEQ ID NO: 27, respectively.
- the antibody of the present invention or a fragment thereof includes the amino acid sequences represented by SEQ ID NOs: 28, 29, and 30 in the light chain of the CDR1, CDR2, and CDR3, respectively, and CDR1, CDR2, and CDR3 of the heavy chain in the light chain.
- the amino acid sequence shown by 31, 32, 33 can be included.
- V L and V H can include the amino acid sequences represented by SEQ ID NO: 34 and SEQ ID NO: 35, respectively.
- the antibody of the present invention or a fragment thereof includes the amino acid sequences represented by SEQ ID NOs: 36, 37, and 38 in the light chain, and CDR1, CDR2, and CDR3 in the heavy chain, respectively.
- the amino acid sequence shown by 39, 40, 41 can be included.
- V L and V H can include the amino acid sequences represented by SEQ ID NO: 42 and SEQ ID NO: 43, respectively.
- modification refers to functional modifications necessary for the antibody or fragment thereof of the present invention to have a specific binding activity with human CXCL1 (for example, glycosylation), and the antibody or fragment thereof of the present invention.
- the antibody label include fluorescent dyes (FITC, rhodamine, Texas red, Cy3, Cy5), fluorescent proteins (eg, PE, APC, GFP), enzymes (eg, horseradish peroxidase, alkaline phosphatase, glucose oxidase), Or labeling with biotin or (strept) avidin).
- the glycosylation of the antibodies of the present invention may also be modified to adjust the affinity of the antibody for the target antigen.
- modification can be accomplished, for example, by altering one or more glycosylation sites within the antibody sequence. More specifically, for example, by removing one or more amino acid substitutions in the amino acid sequence constituting one or more glycosylation sites in FR and removing the glycosylation site, the glycosylation at that site is lost. Can be made.
- Such deglycosylation is effective in increasing the affinity of the antibody for the antigen (US Pat. Nos. 5,714,350 and 6,350,861).
- the monoclonal antibody or fragment thereof used in the measurement method of the present invention is preliminarily cross-reacted with another antigen (protein or fragment thereof) before use in order to ensure specific binding activity to human CXCL1 or fragment thereof. It is preferable to verify the property.
- the antigen to be confirmed for crossing include proteins belonging to the CXC family, particularly human CXCL2 protein and human CXCL3 protein that are structurally similar to human CXCL1.
- an ELISA method using human CXCL1 as an antigen can be used. If the antibody to be tested for reaction specificity, that is, the anti-human CXCL1 monoclonal antibody, and the other antigen protein whose cross-reactivity is to be confirmed coexist in the field of the reaction between the fragment and human CXCL1, the competitive state of the two It is possible to confirm the crossing property by observing. Such a method for confirming the crossing property using the principle of competitive inhibition can quickly perform screening because it is not necessary to prepare reaction systems for all antigens.
- the anti-human CXCL1 monoclonal antibody of the present invention or a hybridoma producing the antibody can be produced by the method described below. However, it is not limited to this method, It can also produce by any other method known in the said field
- A. Method for Producing Anti-human CXCL1 Monoclonal Antibody To produce an anti-human CXCL1 monoclonal antibody that specifically binds to any one of the amino acid partial sequence regions of SEQ ID NOs: 1 to 3 among the amino acid sequences constituting human CXCL1, A monoclonal antibody is prepared using the full length as an immunogen, and then a method for screening an antibody that specifically binds to any one of the amino acid partial sequence regions of SEQ ID NOS: 1 to 3, and previously shown in SEQ ID NOS: 1, 2, or 3 There is a method for producing a monoclonal antibody using a partial sequence of human CXCL1 as an immunogen.
- Human CXCL1 used as an immunogen (antigen) is prepared.
- Human CXCL1 may be any of human CXCL1, in which all or part of the amino acid sequence is chemically synthesized, such as natural, recombinant, or peptide synthesis.
- Natural human CXCL1 is a known protein separation / purification technique such as gel chromatography, ion exchange chromatography, affinity chromatography from human samples including human body fluids such as blood or urine, or culture supernatants of human cultured cells. It can be recovered using graphy.
- Recombinant human CXCL1 can be expressed in microorganisms, insect cells, or animal cells into which DNA encoding the protein has been introduced, and then recovered from the cells using known protein separation / purification techniques.
- Synthetic human CXCL1 can be synthesized, for example, by publicly known techniques such as solid phase peptide synthesis using public human CXCL1 amino acid sequence information.
- the cDNA sequence of human CXCL1 has been published as accession number X12510 in GenBank.
- the synthetic human CXCL1 may be used by linking to a carrier protein such as KLH (Scattle hemocyanin), OVA (ovalbumin), BSA (bovine serum albumin).
- the immunogen may be a natural type or a recombinant type as in the case of immunizing a full-length sequence. Or may be chemically synthesized.
- a partial sequence of natural human CXCL1 is used as an immunogen
- purified human CXCL1 is treated with an appropriate protease such as trypsin, and then peaks are separated and fractionated on a reverse phase column.
- the amino acid sequence of the peptide contained in each sorted peak is determined by a mass spectrometer, and the partial sequence represented by SEQ ID NO: 1, 2, or 3 or a peak that is a part thereof can be used as an immunogen.
- the amino acid partial sequence of recombinant human CXCL1 is used as an immunogen
- the amino acid partial sequence represented by SEQ ID NOs: 1 to 3 or a part thereof is encoded among the DNA sequences encoding human CXCL1 described above.
- human CXCL1 partial sequence the preparation of the amino acid partial sequence of recombinant human CXCL1 represented by SEQ ID NOs: 1 to 3 (hereinafter referred to as human CXCL1 partial sequence) will be described in detail.
- a phage or a plasmid that can autonomously grow in a host microorganism can be used.
- plasmids derived from E. coli pET16b, pGEX6p, pUC118, pUC119, pUC18, pUC19, etc.
- Bacillus subtilis-derived plasmids pUB110, pTP5, etc.
- yeast-derived plasmids YEp13, YEp24, YCp50, etc.
- examples of di include ⁇ phage ( ⁇ gt11, ⁇ ZAP, etc.).
- animal viruses such as vaccinia virus and insect virus vectors such as baculovirus can be used.
- the purified polynucleotide is cleaved with an appropriate restriction enzyme, and a DNA ligase or the like is used inside the vector cleaved with an appropriate restriction enzyme. There is a way to concatenate.
- the obtained human CXCL1 partial sequence expression vector is introduced into a host capable of expressing human CXCL1 protein to obtain a human CXCL1 partial sequence expression transformant.
- the host to be used is not particularly limited as long as it is suitable for the vector used and can express human CXCL1.
- bacteria for example, Escherichia coli
- Bacillus subtilis for example, Bacillus subtilis
- yeast insect cells
- animal cells COS cells
- CHO cells Journal of immunology, 1998), etc. , Vol.160, 3393-3402
- the method for introducing the vector into bacteria is not particularly limited as long as it is a known method for introducing the vector into bacteria, for example, heat shock method, calcium Examples thereof include a method using ions, an electroporation method, etc. All of these techniques are known in the art and described in various literatures, for example, Sambrook, J. et al., 1989, Molecular. Cl ning: See A Laboratory Manual Second Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, and for the transformation of animal cells, the Lipofectin method (PNAS, 86, 1989, PNAS, 86, 1989). (PNAS, 1987, Vol. 84, 7413), electroporation method, calcium phosphate method (Virology, 1973, Vol. 52, 456-467), DEAE-Dextran method and the like are preferably used.
- a human CXCL1 partial sequence expression vector is autonomously replicable in the bacterium, and at the same time, it is composed of a promoter sequence, a ribosome binding sequence, a DNA sequence encoding a human CXCL1 partial sequence, and a transcription termination sequence. It is preferable. Moreover, the gene which codes the regulatory factor which controls a promoter may be contained. Any promoter may be used as long as it can function in a host such as Escherichia coli.
- Human CXCL1 partial sequence expression transformant when a eukaryotic cell such as a yeast, an animal cell, or an insect cell is used as a host, a human CXCL1 partial sequence expression transformant can be similarly obtained according to a technique known in the art.
- Human CXCL1 partial sequence expression vectors used in eukaryotic cells include promoter sequences, DNA sequences encoding human CXCL1 partial sequences, as well as cis elements such as enhancers, splicing signals (donor sites, acceptor sites, branch points, etc.) ), A poly A addition signal, a selection marker sequence, a ribosome binding sequence (SD sequence) and the like may be linked.
- the method of culturing a transformant in a medium is performed according to a usual method used for culturing a host.
- the medium is not particularly limited as long as it contains a carbon source, a nitrogen source, inorganic salts and the like that can be assimilated by the microorganism, and can grow and proliferate.
- Either a natural medium or a synthetic medium can be used. More specific examples include LB medium, but of course not limited thereto.
- an antibiotic such as ampicillin or tetracycline may be added to the medium as necessary.
- the culture is usually carried out at 37 ° C. for 6 to 24 hours under aerobic conditions such as aeration and agitation culture.
- the pH is preferably maintained near neutrality.
- the pH is adjusted using an inorganic or organic acid, an alkaline solution, or the like.
- the transformant is an animal cell such as a CHO cell
- the host cell is inoculated into Gibco's DMEM medium at 1 ⁇ 10 5 cells / mL, and cultured in a 5% CO 2 incubator at 37 ° C. do it.
- an antibiotic such as ampicillin or tetracycline may be added to the medium as necessary.
- the human CXCL1 partial sequence expression vector is a protein expression-inducing vector containing a protein expression control system (for example, when the host is a microorganism, a repressor gene, an operator, etc.), a predetermined expression is given to the transformant. It is necessary to induce the expression of the human CXCL1 partial sequence. Since the expression induction method varies depending on the protein expression control system contained in the vector, an induction process suitable for the system may be performed. For example, the most commonly used protein expression control system in a protein expression inducing vector using a bacterium as a host is a system comprising a lac repressor gene and a lac operator.
- expression can be induced by IPTG (isopropyl-1-thio- ⁇ -D-galactoside) treatment.
- IPTG isopropyl-1-thio- ⁇ -D-galactoside
- an appropriate amount for example, a final concentration of 1 mM
- IPTG isopropyl-1-thio- ⁇ -D-galactoside
- A2 Preparation of production cells of anti-human CXCL1 partial sequence antibody
- the immunogen obtained in A1 is dissolved in a buffer solution to prepare an immunogen solution.
- an adjuvant may be added if necessary for effective immunization.
- adjuvants include commercially available complete Freund's adjuvant (FCA), incomplete Freund's adjuvant (FIA) and the like, and these may be used alone or in combination.
- the prepared immunogen solution is administered to a mammal, for example, a rat, a mouse (for example, a BALB / c of an inbred mouse), a rabbit or the like, and immunized.
- a mammal for example, a rat, a mouse (for example, a BALB / c of an inbred mouse), a rabbit or the like, and immunized.
- the method of administering the immunogen include, but are not limited to, subcutaneous injection using FIA or FCA, intraperitoneal injection using FIA, or intravenous injection using 0.15 mol / L sodium chloride.
- the single dose of the immunogen is appropriately determined according to the type of immunized animal, the route of administration, etc., and is about 30 to 200 ⁇ g per animal.
- the immunization interval is not particularly limited, and after the initial immunization, booster immunization is performed 2 to 6 times, preferably 3 to 4 times at intervals of several days to several weeks, preferably at intervals of 1 to 4 weeks.
- the antibody titer in the serum of the immunized animal is measured by ELISA (Enzyme-Linked Immuno Sorbent Assay) method, etc. If the antibody titer reaches a plateau, the immunogen is injected intravenously or intraperitoneally, Final immunization. Then, antibody-producing cells are collected 2 to 5 days, preferably 3 days after the last immunization.
- Collection of antibody-producing cells from immunized animals and cell fusion Hybridomas that produce monoclonal antibodies that specifically recognize anti-human CXCL1 partial sequences by cell fusion of antibody-producing cells obtained from immunized animals and myeloma cells can be produced.
- Examples of antibody-producing cells include spleen cells, lymph node cells, peripheral blood cells, etc., but spleen cells or local lymph node cells are preferred.
- myeloma cells to be fused with antibody-producing cells generally available cell lines derived from mice and the like can be used.
- the cell line to be used has drug selectivity and cannot survive in a HAT selection medium (including hypoxanthine, aminopterin and thymidine) in an unfused state, and can only grow in a state fused with antibody-producing cells. Those having the following are preferred.
- the cell line is preferably derived from an animal of the same species as the immunized animal. Specific examples of myeloma cells include P3X62-Ag., Which is a hypoxanthine / guanine / phosphoribosyltransferase (HGPRT) deficient cell line derived from BALB / c mice. 8 strain (ATCC CIB9), P3X63-Ag. 8).
- Examples include U1 strain (JCRB9085), P3 / NSI / 1-Ag4-1 strain (JCRB0009), P3x63Ag8.653 strain (JCRB0028) or Sp2 / 0-Ag14 strain (JCRB0029).
- the antibody-producing cell and the myeloma cell are about 1: 1 to 20: 1 in an animal cell culture medium such as DMEM or RPMI1640 medium without serum. Mix at a ratio and perform a fusion reaction in the presence of a cell fusion promoter.
- a cell fusion promoter polyethylene glycol having an average molecular weight of 1,500 to 4,000 Da or the like can be used at a concentration of about 10 to 80%.
- an auxiliary such as dimethyl sulfoxide may be used in combination in order to increase the fusion efficiency.
- antibody-producing cells and myeloma cells can be fused using a commercially available cell fusion device utilizing electrical stimulation (for example, electroporation) (Nature, 1977, Vol. 266, 550-552).
- a cell suspension is obtained using, for example, RPMI 1640 medium containing fetal bovine serum. After appropriate dilution, seed 2 ⁇ 10 6 cells / well on a 96-well microtiter plate, add selective medium to each well, and then perform culture by appropriately exchanging the selective medium.
- the culture temperature is 20 to 40 ° C, preferably about 37 ° C.
- a hybridoma of antibody-producing cells and myeloma cells can be obtained by using a selective medium (HAT medium) containing hypoxanthine, aminopterin, and thymidine. Therefore, cells that grow from about 10 days after the start of culture in a selective medium can be selected as hybridomas.
- HAT medium a selective medium containing hypoxanthine, aminopterin, and thymidine. Therefore, cells that grow from about 10 days after the start of culture in a selective medium can be selected as hybridomas.
- the hybridoma selected in the HAT medium is first screened using the binding activity to natural or recombinant human CXCL1 or the amino acid sequence shown in SEQ ID NOs: 1 to 3 as an index. Subsequently, the hybridoma producing an antibody having binding activity to human CXCL1 is subjected to a cross-ability test. That is, the binding activity to other CXC families and the like is verified, and an acceptable one is selected. Acceptable crossing means a negligible degree of crossing in the intended use of the antibody.
- an ELISA method can be used.
- a microplate on which human CXCL1 or a fragment thereof as an antigen is immobilized is prepared, and a sample obtained by appropriately diluting the culture supernatant of the hybridoma is added thereto and reacted. After sufficiently reacting, the wells are washed, and a secondary antibody label against immunoglobulin is added for further reaction. If the well is washed again and measured using the label of the secondary antibody finally bound to the well, the binding activity of the antibody present in the culture supernatant to the antigen can be quantitatively known.
- the hybridoma of the present invention can be used for antibody production by ascites using a mouse. Specifically, ascites fluid containing antibodies is obtained by inoculating the hybridoma into the abdominal cavity of mice derived from the cells used as the fusion partner used to produce the hybridoma or nude mice, and collecting ascites as appropriate. It can be recovered. More specifically, ascites fluid containing antibodies can be collected by inoculating hybridomas using Sp / 0 cells as fusion partners into the peritoneal cavity of BALB / c mice 10 days after pristane inoculation.
- the hybridoma in this invention can be used for antibody production by culturing using a suitable culture medium.
- the antibody is obtained by inoculating a hybridoma in Gibco's hybridoma SFM medium at 1 ⁇ 10 5 cells / mL and culturing in a 5% CO 2 incubator at 37 ° C. until the hybridoma dies.
- the present invention is not limited to this.
- the antibody or fragment thereof of the present invention utilizes a cDNA sequence encoding the amino acid sequence of a monoclonal antibody that specifically recognizes the human CXCL1 partial sequence disclosed in the present invention. Can also be obtained by recombinant DNA manipulation.
- the nucleotide sequences of V H and V L are arbitrary C L , and each ligated to nucleotide sequence encoding a C H, incorporate each polynucleotide in an appropriate expression vector, after introduction into the host cell can also be expressed as a full immunoglobulin molecule. Also, using CDR graft antibody technology, B2.
- the polynucleotide encoding the amino acid sequence of CDR in the variable region obtained by the above method and the polynucleotide encoding each FR of any immunoglobulin are ligated and incorporated into an appropriate expression vector. It may be expressed as a simple immunoglobulin molecule.
- Each polynucleotide can be synthesized chemically, or the method of Fujimoto et al., which is known as a method for synthesizing long-chain DNA (Hideya Fujimoto, synthetic gene production method, plant cell engineering series 7, plant PCR experiment protocol) 1997, Shujunsha, p. 95-100).
- the sequence of C L , C H , and FR region to be linked is preferably derived from mouse, but derived from any other animal such as human. There may be.
- the heavy chain and the light chain are expressed in the same host cell so that they can be produced as a dimer comprising the heavy chain / light chain.
- cells can be cotransformed with a light chain expression vector and a heavy chain expression vector, and the antibody according to the present invention can be obtained from the transformed cells.
- the polynucleotide encoding the amino acid sequence can be directly incorporated into an appropriate expression vector, introduced into a host cell, and expressed as a fragment of an immunoglobulin molecule.
- recently developed phage display antibody technology (Brinkmann et al, 1995, J Immunol Methods, 182, 41-50, International Publication No.
- WO97 / 13844 that utilizes genetic engineering techniques to express recombinant antibodies on the phage surface.
- a specific antibody can also be obtained by expressing a diversified single chain Fv antibody as a phage fusion protein by artificially shuffling genes encoding heavy and light chains.
- Preparation of a polynucleotide encoding a recombinant anti-human CXCL1 partial sequence monoclonal antibody or a fragment thereof, a vector incorporating the polynucleotide, and a method for introducing the vector into the host were described in “A. Method for producing human CXCL1 antibody” above. Such recombinant DNA techniques known in the art may be used.
- the desired recombinant anti-human CXCL1 antibody or fragment thereof can be obtained from the culture medium of transformed cells or from the cells.
- immunoglobulin expression vectors include, but are not limited to, plasmids, phagemids, cosmids, virus vectors (for example, SV40 virus based vectors, EB virus based vectors, BPV based vectors) and the like.
- virus vectors for example, SV40 virus based vectors, EB virus based vectors, BPV based vectors
- BCMGS Neo vector which is one of the BPV based vectors
- the BCMGS Neo vector which is one of the BPV based vectors, is a desirable vector that efficiently expresses foreign genes by transforming into COS7 cells and the like (Hajime Isayama “Bovine Papillomavirus Vector”, Masami Muramatsu and Hiroshi Okayama Human edition, experimental medicine separate volume: Handbook of genetic engineering, 1991, Yodosha (Japan), 297-299).
- the vector includes control elements (for example, a promoter, an enhancer, a terminator, a polyadenylation site, a splicing site) necessary for expressing the antibody or a fragment thereof, or A selectable marker can be included if desired.
- control elements for example, a promoter, an enhancer, a terminator, a polyadenylation site, a splicing site
- a host cell containing a vector expressing an antibody or a fragment thereof can be produced in the culture supernatant or the host cell by culturing according to a conventional method. Specifically, when CHO cells are used as a host, inoculate the host cells into Gibco DMEM medium at 1 ⁇ 10 5 cells / mL, and culture in a 5% CO 2 incubator at 37 ° C. By this, a culture supernatant containing the antibody can be obtained.
- the host cell is Escherichia coli
- it is inoculated and cultured in a general medium used for culturing Escherichia coli such as LB medium, and the expression of protein is induced to induce the expression of the protein.
- a general medium used for culturing Escherichia coli such as LB medium
- the antibody or fragment thereof as an expression product contains a constant region
- purification and recovery from the culture supernatant or cell disruption solution using a protein A column, protein G column, anti-immunoglobulin antibody affinity column, etc. can do.
- the expression is made only in the variable region and does not include the constant region, so other appropriate purification methods are applied.
- a tag sequence advantageous for purification such as a histidine tag
- it can be purified by affinity chromatography using the corresponding ligand.
- tag fusion protein If it is not a tag fusion protein, it can be purified according to conventional protein purification methods such as ammonium sulfate precipitation, ion exchange chromatography, reverse phase chromatography, gel filtration chromatography, and hydroxyapatite chromatography.
- a decomposition treatment is performed using an appropriate protease such as trypsin. Even after the degradation treatment, the antibody is difficult to be digested with trypsin, so that the antigen-antibody complex can be recovered using Protein G Sepharose or the like.
- the recovered antigen-antibody complex is analyzed by LC-MS to bind to and protect the antibody. The epitope on human CXCL1 that the antibody recognizes, that is, the antibody can be identified.
- the epitope on human CXCL1 recognized by the anti-human CXCL1 monoclonal antibody can be confirmed, for example, by a competition method using a synthetic peptide.
- a synthetic peptide is prepared by a solid phase synthesis method or the like of 4 to 8 amino acids in the amino acid sequence constituting human CXCL1.
- this synthetic peptide was allowed to act when the anti-human CXCL1 monoclonal antibody was reacted with solid phase human CXCL1, and the binding of the anti-human CXCL1 monoclonal antibody was inhibited. It can be determined that the amino acid sequence of the synthetic peptide is an epitope recognized by the anti-human CXCL1 monoclonal antibody.
- Human CXCL1 Detection Method an immunological measurement method for human CXCL1 can be realized by using the thus obtained monoclonal antibody or a fragment thereof.
- the measurement method of the present invention is excellent in specificity for human CXCL1, and can provide an ideal immunological measurement method for human CXCL1.
- sample used in the measurement method of the present invention refers to various samples that can contain human CXCL1.
- human CXCL1 is a cultured cell containing a DNA encoding human CXCL1 or a fragment thereof, a cultured cell lysate, a culture supernatant, or a human sample.
- a human sample is a human-derived living body such as a tissue collected from a human (for example, a post-operatively collected tissue) or a body fluid such as blood, serum, plasma, urine, spinal fluid, saliva, lymph, tears, semen, etc.
- a sample preferably blood, serum, plasma or urine.
- the sample in the present invention may be a solid sample as well as a liquid sample.
- a tissue slice specimen or the like can be used. If the tissue section specimen is subjected to the human CXCL1 measurement method of the present invention, it is convenient because the presence or location of human CXCL1 can be observed in situ.
- any one sequence region of the amino acid sequences represented by SEQ ID NOs: 1 to 3, which are partial sequences of the amino acid sequence constituting human CXCL1, is specifically recognized, and each different sequence region is specifically identified.
- Anti-human CXCL1 that specifically recognizes the amino acid sequence region represented by SEQ ID NO: 3 in combination of two or more, preferably two types of the above-mentioned anti-human CXCL1 partial sequence monoclonal antibodies or fragments thereof It is characterized by being used in combination including a monoclonal antibody.
- Combining anti-human CXCL1 partial sequence monoclonal antibodies or fragments thereof, each of which recognizes a different amino acid sequence region of human CXCL1, contributes to improved detection sensitivity of human CXCL1.
- the immunoassay of the present invention may be performed by a known immunoassay using a labeled antibody such as ELISA, EIA, fluorescence immunoassay, radioimmunoassay or luminescence immunoassay, or surface plasmon resonance method.
- SPR method and quartz crystal microbalance measurement method (QCM method) can be used, but it is preferably applied to immunological measurement methods using labeled antibodies.
- the ELISA method is also called an enzyme immunosorbent assay, which uses an enzyme-labeled antibody or antigen for a very small amount of target antigen contained in a sample, and converts the antigen-antibody reaction to the coloring concentration or fluorescence using the action of the enzyme.
- This is a method of detecting the intensity and quantifying the target antigen. That is, the antibody of the present invention or a fragment thereof, or human CXCL1 or a fragment thereof is immobilized on a solid phase carrier, and an immunological reaction with the antibody or the like, human CXCL1 or the like is enzymatically detected.
- There are methods such as a direct method, an indirect method, and a sandwich method, and the present invention is applied to the sandwich method.
- the solid phase carrier is made of a material such as polystyrene, polycarbonate, polyvinyl toluene, polypropylene, polyethylene, polyvinyl chloride, nylon, polymethacrylate, latex, gelatin, agarose, cellulose, sepharose, glass, metal, ceramics, or magnetic material.
- Insoluble carriers in the form of beads, microplates, test tubes, sticks or test pieces can be used. Immobilization of the antibody of the present invention or a fragment thereof or human CXCL1 or a fragment thereof on a solid phase carrier can be achieved by binding in accordance with a known method such as a physical adsorption method, a chemical binding method, or a combination method thereof.
- labeling substance examples include peroxidase (POD), alkaline phosphatase, ⁇ -galactosidase, urease, catalase, glucose oxidase, lactate dehydrogenase, amylase, biotin-avidin complex, etc.
- POD peroxidase
- alkaline phosphatase alkaline phosphatase
- ⁇ -galactosidase urease
- catalase glucose oxidase
- lactate dehydrogenase lactate dehydrogenase
- amylase biotin-avidin complex
- fluorescein isothiocyanate tetramethylrhodamine isothiocyanate, substituted rhodamine isothiocyanate, dichlorotriazine isothiocyanate, Alexa480 or AlexaFluor 488, etc.
- tritium iodine 125 or iodine 131 Etc.
- NADH-FMNH 2 -luciferase system for the luminescence immunoassay method, NADH-FMNH 2 -luciferase system, luminol-hydrogen peroxide-POD system, acridinium ester system, or dioxetane compound system can be used.
- the binding method between the labeled antigen and the antibody is a known method such as glutaraldehyde method, maleimide method, pyridyl disulfide method or periodic acid method in the case of ELISA, and chloramine T method in the case of radioimmunoassay.
- a known method such as the Bolton Hunter method can be used.
- the immunological measurement method of the present invention is used for the production of immune complex aggregates such as immunoturbidimetric method, latex agglutination reaction, latex turbidimetry, erythrocyte agglutination reaction or particle agglutination reaction.
- Immunoturbidimetric method such as immunoturbidimetric method, latex agglutination reaction, latex turbidimetry, erythrocyte agglutination reaction or particle agglutination reaction.
- a phosphate buffer, glycine buffer, Tris buffer, Good's buffer, or the like can be used as a solvent, and a reaction accelerator such as polyethylene glycol or a nonspecific reaction inhibitor may be included. Good.
- the immunological measurement method of the present invention it is preferable to select and use two types from among the above-mentioned three types of anti-human CXCL1 partial sequence monoclonal antibody or a fragment thereof.
- a specific method will be described by taking as an example the case of using a monoclonal antibody that specifically recognizes the amino acid sequence region represented by SEQ ID NO: 1 and a monoclonal antibody that specifically recognizes the amino acid sequence region represented by SEQ ID NO: 3.
- the embodiment of the present invention is not limited to this.
- a monoclonal antibody that specifically recognizes the amino acid sequence region represented by SEQ ID NO: 1 is immobilized on an insoluble carrier.
- the antibody to be immobilized may be of one type or several types as long as it specifically recognizes the amino acid sequence region represented by SEQ ID NO: 1.
- a sample containing human CXCL1 is allowed to act on the immobilized surface of the antibody to form a complex of the immobilized antibody and human CXCL1 on the surface of the carrier. Thereafter, by sufficiently washing with a washing solution, unbound substances other than human CXCL1 present in the sample are removed.
- a monoclonal antibody labeled body that specifically recognizes the amino acid sequence region represented by SEQ ID NO: 3 is prepared, and the labeled antibody is allowed to act on a carrier to which a complex of the immobilized antibody and human CXCL1 is bound. After sufficiently washing with, human CXCL1 present in the sample can be detected by detecting using a label.
- the labeled antibody may be one type or several types as long as it is a monoclonal antibody that specifically recognizes the amino acid sequence region represented by SEQ ID NO: 3, but it is preferable to use two or more types, It is more preferable to use two types.
- the antibody used for immobilization and the antibody used for labeling can also be used for labeling and immobilization, respectively.
- a sample containing a labeled antibody and human CXCL1 can be mixed first to form an antigen-antibody complex and then allowed to act on the immobilized antibody. If the antibody to be immobilized is labeled with biotin, a biotinylated immobilized antibody, a sample containing human CXCL1, and an antibody with a label other than biotin are mixed together to form an antigen-antibody complex, and then avidin is immobilized on the solid phase. By acting on the immobilized carrier, the antigen-antibody complex can be detected using a label other than biotinylation.
- the immunological measurement method of the present invention can use an immunochromatographic test strip.
- the test strip for immunochromatography includes, for example, a sample receiving portion made of a material that easily absorbs a sample, a reagent portion containing a labeled diagnostic agent of the present invention, a developing portion in which a reaction product of the sample and the diagnostic agent moves, and development It consists of a presentation unit that captures and colors the reaction product.
- Commercially available pregnancy diagnostic agents and the like have the same form.
- the principle of this measurement method is as follows. First, when a sample is given to the sample receiving portion, the sample receiving portion absorbs the sample and causes the sample to reach the reagent portion.
- the above-mentioned anti-human CXCL1 partial sequence monoclonal antibody or a fragment thereof labeled with human CXCL1 in the sample in the reagent part undergoes an antigen-antibody reaction, and the formed reaction complex moves through the development part and reaches the presentation part. .
- the reaction complex is captured by reacting with another type of anti-human CXCL1 partial sequence monoclonal antibody that recognizes a CXCL1 partial sequence different from the labeled monoclonal antibody. Coloration will be recognized.
- the above immunochromatographic test strip is extremely invasive and does not pose any pain or danger to the use of reagents to the user.
- this test strip can be mass-produced at a low cost by a manufacturing method as described in, for example, JP-A-10-54830.
- the surface plasmon resonance phenomenon is a phenomenon in which the intensity of reflected light is significantly attenuated when a metal thin film is irradiated with laser light at a specific incident angle (resonance angle).
- the SPR sensor using the principle of the SPR phenomenon can measure the adsorbate on the surface of the metal thin film with high sensitivity. Therefore, by preliminarily immobilizing antibodies and / or target antigens on the surface of the metal thin film and passing the sample over the surface of the metal thin film, adsorption on the metal surface before and after passing through the sample caused as a result of the antigen-antibody reaction. Differences in objects can be detected.
- a substitution method, an indirect competition method, and the like are known, and any of them may be used. This technique is well known in the art. See, for example, Kazuhiro Nagata and Hiroshi Handa, real-time analysis of biological material interactions, Springer Fairlark Tokyo, Tokyo, 2000.
- the measurement method of the present invention can use a quartz crystal microbalance measurement method (QCM method).
- QCM method utilizes a phenomenon in which when a substance is adsorbed on the surface of an electrode attached to a crystal oscillator, the resonance frequency of the crystal oscillator decreases according to its mass.
- the QCM sensor using this method is a mass measurement sensor that quantitatively captures a very small amount of adsorbed material based on the amount of change in the water resonance frequency.
- This technique is well known in the art. For example, J. et al. Christopher Love, L. A. Estroff, J.M. K. Kriebel, R.A. G. Nuzzo, G.M. M.M.
- Human CXCL1 Detection Kit The present invention can also be used as a kit for carrying out these immunological measurement methods. That is, the antibody or fragment thereof according to the present invention, the antibody, the fragment, a labeled secondary antibody, a substrate necessary for detection of the label, a positive control or a negative control, or a buffer used for dilution or washing of a sample Etc. can be combined into a kit.
- Example 1 Preparation of recombinant human CXCL1 using E. coli (Preparation of human CXCL1 gene)
- human CXCL1 mRNA was first prepared from HEK293 cells.
- Qiasredder and RNeasy mini kit manufactured by Qiagen were used, and the details followed the attached protocol.
- cDNA was synthesized using the obtained total mRNA as a template to prepare a human cDNA library.
- the reverse transcription reaction followed the protocol attached to the enzyme.
- the base sequence represented by SEQ ID NO: 44 contains a part of the 5 'terminal region of the human CXCL1 gene and an NdeI recognition sequence upstream thereof.
- the base sequence represented by SEQ ID NO: 45 includes a part of the 3 'terminal region of the human CXCL1 gene and a BamHI recognition sequence downstream thereof.
- the PCR reaction solution was prepared by using KOD (manufactured by Toyobo Co., Ltd.) as a DNA polymerase according to the protocol attached to KOD so as to contain 10 ng of cDNA library and 10 pmol of each primer.
- the reaction conditions were as follows: heating at 94 ° C. for 10 minutes, repeating 30 cycles of 94 ° C. for 30 seconds, 55 ° C. for 30 seconds, 72 ° C. for 1 minute, and finally holding at 72 ° C. for 4 minutes Performed under conditions.
- the amplified DNA fragment was purified using Quantum prep PCR Kleen Spin Columns (Bio-rad). By this reaction, a PCR product having a total length of about 300 bp was obtained.
- a ligation reaction was performed to incorporate the obtained DNA fragment into a ring-opened pUC118 (Takara Bio Inc.) that had been subjected to HincII cleavage and BAP treatment.
- Ligation High (manufactured by Toyobo Co., Ltd.) was used for DNA ligase, and the reaction followed the attached protocol.
- competent cells were transformed with the solution after the ligation reaction.
- Escherichia coli strain DH5 ⁇ manufactured by Takara Bio Inc.
- the transformed bacteria were spread on an LB plate containing 100 ⁇ g / mL of antibiotic ampicillin and cultured at 37 ° C. overnight.
- the obtained transformant was cultured overnight at 37 ° C. in an LB liquid medium containing 100 ⁇ g / mL ampicillin, and the target pUC118_CXCL1 was obtained by miniprep.
- pUC118_CXCL1 was cleaved with restriction enzymes NdeI and BamHI, and the reaction solution was subjected to agarose electrophoresis. After electrophoresis, a fragment of about 300 bp confirmed by ultraviolet irradiation was excised from the gel, and the DNA fragment was extracted. Extraction was performed using PCR GFX Column (manufactured by GE Healthcare Bioscience). In order to incorporate the extracted DNA fragment into the expression vector pET16b (manufactured by Novagen) (about 6 kb fragment) cleaved with NdeI / BamHI, a ligation reaction was performed. Subsequently, DH5 ⁇ transformation using the solution after the ligation reaction, culturing of the transformant, and miniprep were performed to obtain the target pET16b_CXCL1. Each process followed the above-mentioned method.
- pET16b_CXCL1 was used to transform Escherichia coli strain Rosetta-Gami 2 (Novagen). The obtained transformant was pre-cultured overnight at 37 ° C. in 30 mL of LB medium containing ampicillin and chloramphenicol. Next, 3 L of the same medium is inoculated with the preculture, cultured at 37 ° C. for 3 hours, added with IPTG having a final concentration of 1 mM, and cultured at 32 ° C. for 6 hours to obtain the target recombinant human CXCL1. After inducing expression, the cells were collected by centrifugation.
- the obtained bacterial cells were washed with PBS, and then the insoluble fraction was prepared as a precipitate using B-PER (PIERCE). The details followed the attached protocol. Next, the insoluble fraction was solubilized with Inclusionbody solubilization reagent (manufactured by PIERCE), and histidine tag-fused human CXCL1 was adsorbed using TALON Metal Affinity Resin (manufactured by CLONETECH). The resin adsorbed with protein was washed with PBS containing 10 mM imidazole and then eluted with 1M imidazole solution.
- Example 2 Production and selection of mouse monoclonal antibody against human CXCL1 (Production of anti-human CXCL1 antibody-producing mouse) 100 ⁇ L of the 0.3 mg / mL human CXCL1 solution obtained in Example 1 was mixed with 100 ⁇ L of MPL + TDM Emulsion (manufactured by Corixa), and the whole amount was intraperitoneally administered to 7-week-old BALB / c mice. The same amount of human CXCL1 solution prepared in the same manner was administered after 2 weeks and 4 weeks. Subsequently, 100 ⁇ L of blood was collected from the tail vein of the mouse and allowed to settle overnight, and then centrifuged at 5000 ⁇ g for 5 minutes to collect the supernatant as plasma.
- the suspension was again suspended in RPMI 1640 medium, and the number of cells was counted to prepare an SP2 / 0 myeloma cell solution that was 1/10 the number of spleen cells. Both cell solutions were mixed, centrifuged at 2200 rpm for 10 minutes, and the supernatant was discarded. The cells were tapped to loosen, 1 mL of a solution prepared by mixing PEG (manufactured by ROCHE) and HBSS (manufactured by GIBCO) at a ratio of 5: 1 was added and stirred. In the subsequent work, unless otherwise specified, all solutions and culture media were kept warm at 37 ° C.
- RPMI 1640 medium 9 mL was added over 5 minutes, mixed gently, and then centrifuged at 2200 rpm for 10 minutes to remove the supernatant.
- the obtained precipitated cells are suspended in RPMI 1640 medium supplemented with 15% FCS and HAT (manufactured by ROCHE), poured into a 96-well cell culture plate (manufactured by Greiner) at 200 ⁇ L per well, and incubated at 37 ° C., 5% CO 2 Incubated for 1 week.
- the colony grown under the HAT-added condition is judged as a hybridoma in which spleen cells and myeloma cells are fused, and the supernatant of the well in which the colonies are grown is diluted 5-fold, and 100 ⁇ L is added to the well of the human CXCL1 solid phase plate.
- the presence or absence of antibody production was confirmed by the same method as described above.
- Wells in which antibody production was confirmed were regarded as positive.
- the positive well colonies were suspended in RPMI medium containing 15% FCS and HT (manufactured by Invitrogen), and positive clones were cloned by the limiting dilution method.
- the antibody was produced by acclimation to SFM medium (GIBCO).
- the hybridoma was inoculated to 60 mL of 100% SFM medium at 1 ⁇ 10 5 cells / mL and cultured for 10 days until the cells died, and then the culture was centrifuged at 3000 rpm for 15 minutes to remove the cells. .
- the antibody contained was purified using MabTrapKit (manufactured by GE Healthcare Bioscience).
- the antigen solution was discarded and washed with PBS-T, and then 100 ⁇ L of 50 ⁇ g / mL biotin-labeled anti-human CXCL1 polyclonal antibody (manufactured by R & D SYSTEMS) was placed in the well and allowed to react at room temperature for 1 hour. After discarding the solution in the well and washing with PBS-T, 100 ⁇ L of avidin-HRP solution (R & D SYSTEMS) was reacted at room temperature for 30 minutes. Further, the avidin-HRP solution was discarded, washed with PBS-T, and 100 ⁇ L of TMB solution was added and reacted for 15 minutes.
- biotin-labeled anti-human CXCL1 polyclonal antibody manufactured by R & D SYSTEMS
- the reaction was stopped by adding 100 ⁇ L of 2N sulfuric acid solution. Color development was confirmed by measuring absorbance at 450 nm. The purified antibody in the well having a strong color reaction was judged to be an antibody having high affinity for human CXCL1. As a result, five types of antibodies, IgG1-1, IgG1-3, IgG1-10, IgG1-14, and IgG2b-1, were selected.
- hybridomas producing each antibody were cultured in RPMI 1640 medium supplemented with 15% FCS at 37 ° C. under 5% CO 2 until 1 ⁇ 10 6 cells / mL. Thereafter, the culture solution was centrifuged at 1200 rpm for 5 minutes, and the cells were collected. MRNA was prepared from the recovered hybridoma. For the preparation, Qiaredder and RNeasy mini kit (manufactured by Qiagen)) were used, and the details followed the attached protocol. Next, reverse transcriptase Superscript II (manufactured by Invitrogen)) was used to synthesize cDNA using the obtained total mRNA as a template and an Oligo dT primer to prepare a cDNA library.
- PCR was performed using Mouse Ig Primer (manufactured by Novagen) using the cDNA library obtained for each hybridoma as a template, and the amplification product (mouse immunoglobulin variable region cDNA) was provided by ZERO BLUNT provided by Invitrogen.
- Ligation was performed by inserting into the EcoRI site of PCR TOPO Vector.
- Ligation used Ligation High (manufactured by Toyobo Co., Ltd.) and followed the attached protocol. Competent cells were transformed using the ligation reaction solution. Competent cells were DH5 ⁇ (manufactured by Takara Bio Inc.), and the details were performed according to the attached protocol.
- the bacteria after the transformation treatment were applied to LB plates containing 100 ⁇ g / mL ampicillin and cultured at 37 ° C. overnight.
- Four transformants from each amplification product were inoculated into LB liquid medium containing 100 ⁇ g / mL ampicillin and cultured at 37 ° C. overnight.
- LB liquid medium containing 100 ⁇ g / mL ampicillin and cultured at 37 ° C. overnight.
- four types of vector solutions each incorporating a DNA encoding a monoclonal antibody were obtained for each amplification product.
- the obtained vector solution was subjected to DNA sequence analysis of the region encoding the monoclonal antibody using M13 primer.
- the analysis was performed using a 3130xl genetic analyzer (Applied Biosystems).
- a clone having no stop codon in the insertion region is judged as a DNA sequence encoding the target monoclonal antibody, and the light chain of the five antibodies (IgG1-1, IgG1-3, IgG1-10, IgG1-14, IgG2b-1)
- the DNA sequence of the heavy chain was determined.
- the amino acid sequence encoded according to the codon usage of Escherichia coli was determined, and the sequences shown in SEQ ID NOs: 4 to 43 could be obtained.
- SEQ ID NOs: 36 to 43 were obtained as amino acid sequences encoding IgG1-1. More particularly, SEQ ID NOs: 36, 37, and 38 encode the light chain CDR1, CDR2, and CDR3 of IgG1-1, respectively. SEQ ID NOs: 39, 40, and 41 encode the same heavy chain CDR1, CDR2, and CDR3 of IgG1-1, respectively. SEQ ID NOs: 42 and 43 encode the full length of the light chain variable region and the full length of the heavy chain variable region of IgG1-1, respectively.
- amino acid sequences shown in SEQ ID NOs: 28 to 35 were obtained as amino acid sequences encoding IgG1-3. More specifically, SEQ ID NOs: 28 to 33 sequentially encode IgG1-3 light chain CDR1 to heavy chain CDR1 to CDR3. SEQ ID NOs: 34 and 35 encode the entire light chain variable region and heavy chain variable region of IgG1-3, respectively.
- amino acid sequences shown in SEQ ID NOs: 4 to 11 were obtained as amino acid sequences encoding IgG1-10. More specifically, SEQ ID NOs: 4 to 9 sequentially encode IgG1-10 light chain CDR1 to heavy chain CDR1 to CDR3. SEQ ID NOs: 10 and 11 encode the entire light chain variable region and heavy chain variable region of IgG1-10, respectively.
- amino acid sequences shown in SEQ ID NOs: 20 to 27 were obtained as amino acid sequences encoding IgG1-14. More specifically, SEQ ID NOs: 20 to 25 sequentially encode IgG1-14 light chain CDR1-3 and heavy chain CDR1-3. SEQ ID NOs: 26 and 27 encode the entire light chain variable region and heavy chain variable region of IgG1-14, respectively.
- amino acid sequences shown in SEQ ID NOs: 12 to 19 were obtained as amino acid sequences encoding IgG2b-1. More specifically, SEQ ID NOs: 12 to 17 sequentially encode IgG2b-1 light chain CDR1 to heavy chain CDR1 to CDR3. SEQ ID NOs: 18 and 19 respectively encode the full length of the light chain variable region and the full length of the heavy chain variable region of IgG2b-1.
- Example 3 Analysis of partial sequence of human CXCL1 recognized by selected antibody
- Example 3 Analysis of partial sequence of human CXCL1 recognized by selected antibody
- the epitope on the recognized amino acid sequence of human CXCL1 was analyzed.
- DTT was added to 100 ⁇ L of 1 ⁇ g / ⁇ L human CXCL1 solution to a final concentration of 10 mM, reacted at 95 ° C. for 5 minutes to reduce disulfide bonds in CXCL1, and then iodine with a final concentration of 20 mM.
- Acetamide was added, and thiol group alkylation reaction was carried out at 37 ° C. under light-shielding conditions for 30 minutes.
- 20 ⁇ g of each of the antibodies selected in Example 2 was added to 12 ⁇ g of the resulting reduced alkylated human CXCL, and the volume was increased to 100 ⁇ L of 100 mM Tris-HCl buffer (pH 8.0), followed by reaction at room temperature for 1 hour with stirring and mixing. I let you.
- trypsin manufactured by Promega
- aminopeptidase M manufactured by ROCHE
- carboxypeptidase Y manufactured by ROCHE
- the antigen-antibody complex was eluted with 100 ⁇ L of 0.1% formic acid, and Q-TOF Premier (manufactured by Waters-MicroMass) was used as the eluate. LC-MS analysis was performed using this. Analysis followed the protocol attached to the instrument.
- Example 4 Detection of human CXCL1 by sandwich ELISA using monoclonal antibody IgG2b-1 and monoclonal antibody IgG1-10 From Example 3, it was found that the amino acid sequence region represented by SEQ ID NO: 1 was specifically recognized.
- the human CXCL1 was measured by sandwich ELISA using the antibody IgG2b-1 and the biotin-labeled antibody IgG1-10, which was found to specifically recognize the amino acid sequence region shown in SEQ ID NO: 3.
- Biotinylation of IgG1-10 was performed using Sulfo-NHS Biotin (manufactured by PIERCE), and the details followed the attached protocol.
- a 10 ⁇ g / mL PBS solution of IgG2b-1 was prepared, and then 100 ⁇ L each was put into a well of a 96-well polystyrene plate (manufactured by Greiner) and immobilized overnight. On the next day, the solution was discarded, 200 ⁇ L of 1% BSA-PBS solution (manufactured by SIGMA) was poured, and the mixture was allowed to stand at room temperature for 1 hour. Thereafter, the plate was washed with PBS-T to obtain a purified antibody-immobilized plate.
- Example 5 Detection of human CXCL1 by sandwich ELISA using monoclonal antibody IgG2b-1 and monoclonal antibody IgG1-14 From Example 3, it was found that the amino acid sequence region represented by SEQ ID NO: 1 was specifically recognized.
- Human CXCL1 was measured by sandwich ELISA using the monoclonal antibody IgG2b-1 and the biotin-labeled monoclonal antibody IgG1-14, which was found to specifically recognize the amino acid sequence region shown in SEQ ID NO: 3. .
- IgG1-14 biotinylation and sandwich ELISA were performed in the same manner as in Example 4. The results are shown in FIG.
- Example 6 Detection of human CXCL1 by sandwich ELISA using monoclonal antibody IgG1-3 and monoclonal antibody IgG1-14 From Example 3, it was found that the amino acid sequence region shown in SEQ ID NO: 2 was specifically recognized.
- Human CXCL1 was measured by sandwich ELISA using the antibody IgG1-3 and the biotin-labeled antibody IgG1-14, which was found to specifically recognize the amino acid sequence region shown in SEQ ID NO: 3.
- IgG1-14 biotinylation and sandwich ELISA were performed in the same manner as in Example 4. The results are shown in FIG.
- Human CXCL1 detection by sandwich ELISA method using a commercially available kit Recombinant human CXCL1 was measured using Human CXCL1 / GRO alpha DuoSet (manufactured by R & D SYSTEMS), which is a commercially available human CXCL1 detection kit.
- the kit immobilizes an anti-human CXCL1 mouse monoclonal antibody (recognizing the amino acid sequence represented by SEQ ID NO: 2) and uses a biotinylated labeled goat polyclonal antibody for detection.
- the solid phase was applied to a 96-well polystyrene plate manufactured by Greiner, and the detailed experimental procedure followed the attached protocol. The results are shown in FIG. 1, FIG. 4 and FIG.
- Example 7 Detection of human CXCL1 by sandwich ELISA using a mixed solution of monoclonal antibody IgG2b-1 and monoclonal antibodies IgG1-10 and IgG1-14 From Example 3, the amino acid sequence region represented by SEQ ID NO: 1 Antibody IgG2b-1, which was found to specifically recognize, and biotin-labeled antibody IgG1-10, which was found to specifically recognize the amino acid sequence region shown in SEQ ID NO: 3, or IgG-10 and IgG1- Human CXCL1 was measured by a sandwich ELISA method using a mixture of biotin-labeled compounds each labeled with 14 biotin. Antibody biotinylation and sandwich ELISA were performed as in Example 4. The result is shown in FIG.
- the signal at each concentration is higher than that of one antibody at the same concentration. It was found that the measurement sensitivity of human CXCL1 was increased by using two types of labeled antibodies to be recognized rather than using one type.
- Example 8 Detection of human CXCL1 added to urine by sandwich ELISA using monoclonal antibody IgG2b-1 and monoclonal antibody IgG1-10 or IgG1-14 From Example 3, the amino acid sequence represented by SEQ ID NO: 1 Antibody IgG2b-1, which was found to specifically recognize the region, and biotin-labeled antibody IgG1-10, which was found to specifically recognize the amino acid sequence region shown in SEQ ID NO: 3, or IgG1-14 Human CXCL1 added to urine was measured by sandwich ELISA using a biotin-labeled product.
- Biotinylation of IgG1-10 and IgG1-14 was performed using Sulfo-NHS Biotin (manufactured by PIERCE), and the details followed the attached protocol.
- a 10 ⁇ g / mL PBS solution of IgG2b-1 was prepared, and then 100 ⁇ L each was put into a well of a 96-well polystyrene plate (manufactured by Greiner) and immobilized overnight. The next day, the solution was discarded, 200 ⁇ L of 1% BSA-PBS solution (manufactured by SIGMA) was poured, and the mixture was allowed to stand at room temperature for 1 hour.
- the plate was washed with PBS-T to obtain a purified antibody-immobilized plate.
- recombinant human CXCL1 was added to human urine collected on that day so that it would be 250 pg / mL, and 100 ⁇ L of antigen-added urine serially diluted with the human urine to 3.9 pg / mL was added to each well.
- the reaction was performed at room temperature for 1 hour.
- the antigen solution in the well was discarded and washed with PBS-T, and then 100 ⁇ L of 1 ⁇ g / mL biotin-labeled IgG1-10 diluted with 1% BSA-PBS was reacted at room temperature for 1 hour.
- Example 9 Detection of human CXCL1 added to urine by sandwich ELISA using monoclonal antibody IgG1-3 and monoclonal antibody IgG1-14 From Example 3, the amino acid sequence region shown in SEQ ID NO: 2 was specifically identified. Added to urine by sandwich ELISA using antibody IgG1-3 identified to be recognized and biotinylated antibody IgG1-14 identified to specifically recognize the amino acid sequence region shown in SEQ ID NO: 3 The human CXCL1 was measured. Antibody biotinylation and sandwich ELISA were performed as in Example 8. The results are shown in FIG.
- Example 10 Detection of CXCL1 by sandwich ELISA using a commercially available kit monoclonal antibody and monoclonal antibody IgG1-10 Commercially available kit that was found to specifically recognize the amino acid sequence region shown in SEQ ID NO: 2 in Example 3 Sandwich using a mouse monoclonal antibody attached to Human CXCL1 / GRO alpha DuoSet (manufactured by R & D SYSTEMS) and a biotin-labeled antibody IgG1-10 that was found to specifically recognize the amino acid sequence region shown in SEQ ID NO: 3. The human CXCL1 added to the buffer solution by ELISA was measured.
- Biotinylation of IgG1-10 was performed using Sulfo-NHS Biotin (manufactured by PIERCE), and the details followed the attached protocol.
- a 4 ⁇ g / mL PBS solution of a mouse monoclonal antibody attached to a commercially available kit was prepared, and then 100 ⁇ L each was put into a well of a 96-well polystyrene plate (manufactured by Greiner) and solidified overnight. The next day, the solution was discarded, 200 ⁇ L of 1% BSA-PBS solution (manufactured by SIGMA) was poured, and the mixture was allowed to stand at room temperature for 1 hour.
- the plate was washed with PBS-T to obtain a purified antibody-immobilized plate.
- 100 ⁇ L of an antigen solution serially diluted with 1% BSA-PBS from 500 pg / mL to 7.8 pg / mL of recombinant human CXCL1 was added to each well and allowed to react at room temperature for 1 hour.
- the antigen solution in the well was discarded and washed with PBS-T, and then 100 ⁇ L of 1 ⁇ g / mL biotin-labeled IgG1-10 diluted with 1% BSA-PBS was reacted at room temperature for 1 hour.
- Example 11 Detection of human CXCL1 by ELISA using the obtained antibody About the five types of antibodies IgG1-1, IgG1-3, IgG1-10, IgG1-14, IgG2b-1 selected in Example 2, Each 10 ⁇ g / mL PBS solution was prepared, and 100 ⁇ L each was put into a well of a 96-well polystyrene plate (manufactured by Greiner) and solidified overnight. The next day, the solution was discarded, 200 ⁇ L of 1% BSA-PBS solution (manufactured by SIGMA) was poured, and the mixture was allowed to stand at room temperature for 1 hour.
- 1% BSA-PBS solution manufactured by SIGMA
- the plate was washed with PBS-T to obtain a purified antibody-immobilized plate.
- 100 ⁇ L of an antigen solution obtained by serially diluting recombinant human CXCL1 protein from 125 pg / mL to 15 pg / mL with 1% BSA-PBS was added to each well and allowed to react at room temperature for 1 hour.
- the antibodies IgG1-1, IgG1-3, IgG1-10, IgG1-14, and IgG2b-1 of the present invention all have strong signals compared to commercially available antibodies, and human CXCL1 It was found that the detectability of was high.
- Example 12 Detection of human CXCL1 in plasma using the obtained antibodies Using the five types of antibodies IgG1-1, IgG1-3, IgG1-10, IgG1-14, and IgG2b-1 selected in Example 2 Then, human CXCL1 dissolved in plasma was detected.
- a 10 ⁇ g / mL PBS solution was prepared for each antibody, and then 100 ⁇ L each was put into a well of a 96-well polystyrene plate (manufactured by Greiner) and solidified overnight. On the next day, the solution was discarded and 200 ⁇ L of 4% diluted 1% BSA-PBS solution (manufactured by SIGMA) was poured and allowed to stand at room temperature for 1 hour. Thereafter, the plate was washed with PBS-T to obtain a purified antibody-immobilized plate.
- a plasma solution of 500 pg / mL recombinant human CXCL1 protein was prepared, and a dilution series of antigen plasma solution was prepared by serial dilution with the same plasma up to 125 pg / mL. 100 ⁇ L of this was added to each well and reacted at room temperature for 1 hour, and then the antigen solution was discarded and washed with PBS-T.
- Example 13 Detection of human CXCL1 in urine using the obtained antibody Using five types of antibodies IgG1-1, IgG1-3, IgG1-10, IgG1-14, and IgG2b-1 selected in Example 2 Then, human CXCL1 dissolved in urine was detected.
- a 10 ⁇ g / mL PBS solution was prepared for each antibody, and then 100 ⁇ L each was put into a well of a 96-well polystyrene plate (manufactured by Greiner) and solidified overnight. On the next day, the solution was discarded and 200 ⁇ L of 4% diluted 1% BSA-PBS solution (manufactured by SIGMA) was poured and allowed to stand at room temperature for 1 hour. Thereafter, the plate was washed with PBS-T to obtain a purified antibody-immobilized plate.
- a urine solution of 500 pg / mL recombinant human CXCL1 protein was prepared, and a dilution series of antigen urine solution was prepared by serial dilution with the same urine up to 125 pg / mL. 100 ⁇ L of this was added to each well and reacted at room temperature for 1 hour, and then the antigen solution was discarded and washed with PBS-T.
- Example 14 Neutralization activity measurement experiment of invasive ability of bladder cancer cells using monoclonal antibodies IgG1-1, IgG1-3, IgG1-10, IgG1-14, IgG2b-1 Five types selected in Example 2 The antibodies IgG1-1, IgG1-3, IgG1-10, IgG1-14, and IgG2b-1 were measured for neutralizing activity to suppress the invasive ability of bladder cancer cells.
- T24 cells which are bladder cancer cells, were inoculated into RPMI1640 medium supplemented with 10% FCS and 12.5 mM HEPES at 1.0 ⁇ 10 5 cells / mL, and precultured for 40 hours. After the culture, the cells were collected, and the invasive ability of the cell solution mixed with each antibody was measured using a Matrigel invasion chamber (BD Falcon). Details follow the attached protocol. In the Matrigel invasion chamber, each antibody was added to a PBS suspension of 2.0 ⁇ 10 5 cells / mL so that the final concentration would be 10 ⁇ g / mL. Invasion culture was performed for 5 hours.
- the lower part of the chamber was stained with a diffic reagent (manufactured by Sysmex), and the number of bladder cancer cells infiltrating to the lower part of the chamber was counted.
- Example 15 Neutralization activity measurement experiment 2 of bladder cancer cells using monoclonal antibodies IgG1-3, IgG1-10, IgG1-14, IgG2b-1 Among the five types of antibodies selected in Example 2, four types of IgG1-3, IgG1-10, IgG1-14, and IgG2b-1 were measured for neutralizing activity to suppress the invasive ability of bladder cancer cells. It was. Unlike Example 14, the antibody was mixed from the pre-culture stage, not immediately before the measurement of invasive ability.
- T24 cells which are bladder cancer cells, were inoculated into RPMI1640 medium supplemented with 10% FCS and 12.5 mM HEPES so as to be 1.0 ⁇ 10 5 cells / mL, and each was adjusted to a final concentration of 10 ⁇ g / mL.
- the cells were cultured for 40 hours.
- the cells were collected, and the invasive ability of the cell solution mixed with each antibody was measured using a Matrigel invasion chamber (BD Falcon). Thereafter, the same experiment as in Example 14 was performed, and only the infiltration culture time was changed to 6.5 hours. The number of infiltrated cells was also measured in the same manner as in Example 14, and the results are shown in FIG.
- Comparative Example 6 Experiment 2 for measuring neutralizing activity of invasive ability of bladder cancer cells using a commercially available antibody With respect to MAB275 (manufactured by R & D SYSTEMS), which is a commercially available anti-human CXCL1 monoclonal antibody, the neutralizing activity for suppressing the invasive ability of bladder cancer cells was measured. Unlike Comparative Example 7, the antibody was mixed from the pre-culture stage, not just before the measurement of invasive ability. The method was the same as in Example 15. The results are shown in FIG.
- the concentration of human CXCL1 can be measured with higher sensitivity than before, it can be used for detection of cancer such as urothelial cancer.
Abstract
Description
本明細書で使用する用語「ヒトCXCL1」とは、Genbank NM_001511に記載のアミノ酸配列からなるタンパク質又はその天然変異体を意味する。ここでいう「天然変異体」とは、自然界に存在する変異体であって、例えば、前記アミノ酸配列において1個又は数個のアミノ酸が欠失、置換、又は付加されたもの、前記アミノ酸配列と95%以上、好ましくは98%以上、より好ましくは99%以上の同一性を有するものなどをいう。ここで「同一性」とは、二つのアミノ酸配列にギャップを導入して、又は導入しないで最も高い一致度となるように整列(アラインメント)させたときに、前記ギャップの数を含めた、一方のアミノ酸配列の全アミノ酸残基数に対する他方のアミノ酸配列の同一アミノ酸残基数の割合(%)をいう。また、「数個」とは、2~10の整数、例えば、2~7、2~5、2~4、2~3の整数をいう。天然変異体の具体例としては、SNP(一塩基多型)等の多型に基づく変異体やスプライス変異体などが挙げられる。前記置換は、保存的アミノ酸置換であることが好ましい。保存的アミノ酸置換であれば、前記アミノ酸配列を有するヒトCXCL1と実質的に同等な構造又は性質を有しうるからである。保存的アミノ酸とは、互いに、非極性アミノ酸(グリシン、アラニン、フェニルアラニン、バリン、ロイシン、イソロイシン、メチオニン、プロリン、トリプトファン)及び極性アミノ酸(非極性アミノ酸以外のアミノ酸)、荷電アミノ酸(酸性アミノ酸(アスパラギン酸、グルタミン酸)及び塩基性アミノ酸(アルギニン、ヒスチジン、リジン))及び非荷電アミノ酸(荷電アミノ酸以外のアミノ酸)、芳香族アミノ酸(フェニルアラニン、トリプトファン、チロシン)、分岐状アミノ酸(ロイシン、イソロイシン、バリン)、ならびに脂肪族アミノ酸(グリシン、アラニン、ロイシン、イソロイシン、バリン)などが知られている。
本発明の抗ヒトCXCL1モノクローナル抗体又はその抗体を産生するハイブリドーマは、以下に記載する方法によって作製することができる。ただし、本方法に限定されるものではなく、当該分野で公知の他のあらゆる方法で作製することもできる。
ヒトCXCL1を構成するアミノ酸配列のうち、配列番号1~3のいずれかのアミノ酸部分配列領域と特異的に結合する抗ヒトCXCL1モノクローナル抗体を作製するには、ヒトCXCL1の全長を免疫原としてモノクローナル抗体を作製し、その後、配列番号1~3のいずれかのアミノ酸部分配列領域と特異的に結合する抗体をスクリーニングする方法と、予め配列番号1、2、又は3で示されるヒトCXCL1の部分配列を免疫原としてモノクローナル抗体を作製する方法がある。
まず、免疫原(抗原)として用いるヒトCXCL1を調製する。ヒトCXCL1は、天然型、組換え型、又はペプチド合成のようにアミノ酸配列の全部又は一部を化学的に合成したヒトCXCL1のいずれであってもよい。
本ポリヌクレオチドの調製方法については、下記実施例1において詳述しているため、ここでは省略する。
得られたヒトCXCL1部分配列発現ベクターを、ヒトCXCL1タンパク質を発現し得る宿主中に導入して、ヒトCXCL1部分配列発現形質転換体を得る。使用する宿主については、使用したベクターに適する宿主であって、ヒトCXCL1を発現できるものであれば特に限定されるものではない。例えば、細菌(大腸菌(例えば、エシェリヒア・コリ:Escherichia coli)、枯草菌(例えば、バチルス・サブチリス(Bacillus subtilis)等)、酵母、昆虫細胞、動物細胞(COS細胞、CHO細胞(Journal of immunology、1998、Vol.160、3393-3402)などが好適に用いられる。細菌への前記ベクターの導入方法は、細菌に該ベクターを導入する公知の方法であれば特に限定されない。例えば、ヒートショック法、カルシウムイオンを用いる方法、エレクトロポレーション法等が挙げられる。これらの技術は、いずれも当該分野で公知であり、様々な文献に記載されている。例えば、Sambrook、J. et.al、1989、Molecular Cloning: A Laboratory Manual Second Ed.、Cold Spring Harbor Laboratory Press、Cold Spring Harbor、New Yorkを参照されたい。また、動物細胞の形質転換には、リポフェクチン法(PNAS、1989、Vol.86、6077)、(PNAS、1987、Vol.84、7413)、エレクトロポレーション法、リン酸カルシウム法(Virology、1973、Vol.52、456-467)、DEAE-Dextran法等が好適に用いられる。
続いて、上記作製した形質転換体を培養する。形質転換体を培地で培養する方法は、宿主の培養に用いられる通常の方法に従って行われる。例えば、微生物を宿主とする場合、培地は、微生物が資化し得る炭素源、窒素源、無機塩類等を含有し、かつ生育、増殖可能なものであれば、特に限定はしない。天然培地、合成培地のいずれを用いることもできる。より具体的な例としては、LB培地が挙げられるが、もちろんこれに限定はされない。また、形質転換体の培養を選択的に行うために、必要に応じてアンピシリンやテトラサイクリン等の抗生物質を培地に添加してもよい。培養は、通常、通気攪拌培養などの好気的条件下、37℃で6~24時間行う。培養期間中、pHは中性付近に保持することが好ましい。pHの調整は、無機又は有機酸、アルカリ溶液等を用いて行う。形質転換体がCHO細胞等の動物細胞である場合には、Gibco社製DMEM培地に1×105細胞/mLとなるように宿主細胞を接種し、37℃の5%CO2インキュベータにて培養すればよい。培養中は必要に応じてアンピシリンやテトラサイクリン等の抗生物質を培地に添加してもよい。
培養後、ヒトCXCL1部分配列が菌体内又は細胞内に生産される場合には、菌体又は細胞を回収して破砕することによりタンパク質を抽出することができる。また、ヒトCXCL1部分配列が菌体外又は細胞外に生産される場合には、培養液をそのまま使用するか、遠心分離等により菌体又は細胞を除去し、上清を使用すればよい。その後、一般的なタンパク質の精製方法、例えば硫酸アンモニウム沈殿、ゲルクロマトグラフィー、イオン交換クロマトグラフィー、アフィニティークロマトグラフィー等を単独で、又は適宜組合せて用いることにより、前記培養物中からヒトCXCL1を単離精製することができる。ヒトCXCL1部分配列が得られたか否かは、SDS-ポリアクリルアミドゲル電気泳動等により確認すればよい。
A1で得られた免疫原を、緩衝液に溶解して免疫原溶液を調製する。この際、免疫を効果的に行うために、必要であればアジュバントを添加してもよい。アジュバントの例としては、市販の完全フロイントアジュバント(FCA)、不完全フロイントアジュバント(FIA)等が挙げられ、これらを単独で又は混合して用いてもよい。
B1.免疫動物からの抗体産生細胞の回収と細胞融合
免疫動物から得た抗体産生細胞とミエローマ細胞との細胞融合を行うことで、抗ヒトCXCL1部分配列を特異的に認識するモノクローナル抗体を生産するハイブリドーマを作製することができる。抗体産生細胞としては、脾臓細胞、リンパ節細胞、末梢血細胞等が挙げられるが、脾臓細胞又は局所リンパ節細胞が好ましい。抗体産生細胞と融合させるミエローマ細胞としては、一般に入手可能なマウスなど由来の株化細胞を使用することができる。使用する細胞株としては、薬剤選択性を有し、未融合の状態ではHAT選択培地(ヒポキサンチン、アミノプテリン、チミジンを含む)で生存できず、抗体産生細胞と融合した状態でのみ生育できる性質を有するものが好ましい。また、株化細胞は、免疫動物と同種系の動物に由来するものが好ましい。ミエローマ細胞の具体例としては、BALB/cマウス由来のヒポキサンチン・グアニン・ホスホリボシル・トランスフェラーゼ(HGPRT)欠損細胞株である、P3X62-Ag.8株(ATCCTIB9)、P3X63-Ag.8.U1株(JCRB9085)、P3/NSI/1-Ag4-1株(JCRB0009)、P3x63Ag8.653株(JCRB0028)又はSp2/0-Ag14株(JCRB0029)などが挙げられる。
細胞融合処理後の細胞から目的とする抗ヒトCXCL1部分配列モノクローナル抗体を産生するハイブリドーマを選別する方法としては、細胞懸濁液を、例えば、ウシ胎児血清含有RPMI1640培地などで適当に希釈後、96ウェルマイクロタイタープレート上に2×106個/ウェル程度まき、各ウェルに選択培地を加え、以後適当に選択培地を交換して培養を行う。培養温度は20~40℃、好ましくは約37℃である。ミエローマ細胞がHGPRT欠損株又はチミジンキナーゼ(TK)欠損株のものである場合には、ヒポキサンチン・アミノプテリン・チミジンを含む選択培地(HAT培地)を用いることにより、抗体産生細胞とミエローマ細胞のハイブリドーマのみを選択的に生育、増殖させることができるため、選択培地で培養開始後約10日前後から生育してくる細胞をハイブリドーマとして選択することができる。
本発明におけるハイブリドーマは、マウスを用いて腹水化することにより抗体生産に用いることが出来る。具体的には、ハイブリドーマを作製する際に用いた融合パートナーに用いた細胞の由来のマウスや、ヌードマウスの腹腔内にハイブリドーマを接種し、腹水を適宜採取することにより、抗体を含む腹水液を回収することができる。より具体的には、Sp/0細胞を融合パートナーとしたハイブリドーマを、プリスタン接種後10日間を経たBALB/cマウスの腹腔中に接種することにより、抗体を含む腹水液を回収できる。
本発明の抗体又はその断片は、本発明で開示されたヒトCXCL1部分配列を特異的に認識するモノクローナル抗体のアミノ酸配列をコードするcDNA配列を利用して、組換えDNA操作によって得ることもできる。
得られた抗ヒトCXCL1モノクローナル抗体が認識するヒトCXCL1上のエピトープは、次のような方法によって確認することもできる。
本発明では、このようにして得られたモノクローナル抗体、あるいはその断片を用いることにより、ヒトCXCL1の免疫学的測定方法を実現できる。本発明の測定方法はヒトCXCL1に対する特異性に優れ、ヒトCXCL1の理想的な免疫学的測定方法を提供することができる。
また、本発明は、これら免疫学的な測定方法を実施するためのキットとして使用することができる。すなわち、本発明による抗体やその断片をはじめとして、該抗体や該断片、標識二次抗体、さらには標識の検出に必要な基質、陽性対照や陰性対照、あるいは試料の希釈や洗浄に用いる緩衝液等を組合せてキットとすることができる。
(ヒトCXCL1遺伝子の調製)
抗体の免疫原として用いる組換え型ヒトCXCL1を調製するために、まず、HEK293細胞より、ヒトCXCL1 mRNAの調製を行った。mRNAの調製は、Qiashredder及びRNeasy mini kit(Qiagen社製)を使用し、詳細は付属のプロトコールに従った。
組換え型ヒトCXCL1を調製するために、pET16b_CXCL1を用いて、大腸菌株Rosetta-Gami 2(Novagen社製)の形質転換を行った。得られた形質転換体を、アンピシリン及びクロラムフェニコールを含むLB培地30mLで37℃にて一晩前培養を行った。次に、3Lの同培地に前培養を接種し、37℃にて3時間培養し、終濃度1mMのIPTGを添加して32℃にて6時間培養を行い、目的の組換え型ヒトCXCL1の発現を誘導させた後、遠心分離により菌体を回収した。
(抗ヒトCXCL1抗体産生マウスの作製)
実施例1で得られた100μLの0.3mg/mLヒトCXCL1溶液を100μLのMPL+TDM Emulsion(Corixa社製)と混合し、全量を7週齢のBALB/cマウスに腹腔投与した。2週間後、及び4週間後に同様に調製したヒトCXCL1溶液を同量投与した。続いて、マウス尾部静脈より血液を100μL採取し、一晩清置した後、5000×gで5分遠心して上清を血漿として回収した。
ヒトCXCL1に対する抗体の産生が確認されたマウスについて、上記と同様に調製したヒトCXCL1溶液を腹腔投与し、3日後に脾臓の摘出を行った。摘出した脾臓にシリンジで穴を開け、RPMI1640培地(GIBCO社製)を注入して脾臓細胞を押し出し、脾臓細胞液を得た。得られた脾臓細胞液を1200rpmで7分間遠心した後に上清を除去し、RPMI1640培地にて洗浄した。再びRPMI1640培地に懸濁して細胞数をカウントし、脾臓細胞数の1/10量のSP2/0ミエローマ細胞液を調製した。両細胞液を混合し、2200rpmで10分遠心し、上清を廃棄した。細胞をタッピングしてほぐし、PEG(ROCHE社製)とHBSS(GIBCO社製)を5:1で混合した溶液を1mL添加して攪拌した。以降の作業では、特に断りがない限り、溶液や培地は全て37℃で保温したものを用いた。
前記75種類の精製抗体について、次のような手法でヒトCXCL1と親和性の高い抗体を選抜した。まず、それぞれの精製抗体について10μg/mL溶液を調製し、それぞれ100μLずつ96ウェルポリスチレンプレート(グライナー社製)のウェルに入れ、一晩固相化した。ウェル内の精製抗体溶液を廃棄後、4倍に希釈したBlockAce溶液(大日本住友製薬社製)を200μL注ぎ、1時間、室温で静置した。その後、溶液を廃棄し、PBS‐Tにて洗浄したものを精製抗体固相化プレートとした。次に、組換え型ヒトCXCL1を1000pg/mLから15pg/mLまで段階希釈した抗原溶液を前記精製抗体固相化プレートの各ウェルに100μLずつ添加し、1時間、室温で反応させた。続いて、抗原溶液を廃棄してPBS-Tで洗浄した後、100μLの50μg/mLビオチン標識抗ヒトCXCL1ポリクローナル抗体(R&DSYSTEMS社製)をウェルに入れ、1時間、室温で反応させた。ウェル内の溶液を廃棄してPBS‐Tで洗浄後、100μLのavidin‐HRP溶液(R&DSYSTEMS社製)を30分間室温で反応させた。さらに、avidin-HRP溶液を廃棄し、PBS-Tにて洗浄後、TMB溶液100μLを入れて15分反応させた。反応の停止は、100μLの2N硫酸溶液の添加によって行った。発色は、450nmの吸光度の測定により確認した。発色反応が強かったウェルの精製抗体をヒトCXCL1との親和性が高い抗体と判断した。この結果、IgG1-1、IgG1-3、IgG1-10、IgG1-14、IgG2b-1の5種類の抗体を選抜した。
選抜した5種類の抗体について、軽鎖及び重鎖のcDNA配列とアミノ酸配列を決定した。まず、それぞれの抗体を産生するハイブリドーマを、15%FCSを添加したRPMI1640培地を用いて、37℃、5%CO2下で1×106細胞/mLになるまで培養した。その後、培養液を1200rpm、5分間遠心分離し、細胞を回収した。回収したハイブリドーマよりmRNAを調製した。調製は、Qiashredder及びRNeazy mini kit(Qiagen社製))を使用し、詳細は付属のプロトコールに従った。次に、逆転写酵素SuperscriptII(invitrogen社製))を用いて、得られたTotal mRNAを鋳型にOligo dTプライマーを用いてcDNAを合成し、cDNAライブラリーを作製した。
実施例2にて選抜した5つの抗体について、認識するヒトCXCL1アミノ酸配列上のエピトープの解析を行った。
市販のヒトCXCL1検出キットであるHuman CXCL1/GRO alpha DuoSet(R&DSYSTEMS社製)に固相化用抗体として添付されているモノクローナル抗体について、実施例3と同様に認識するヒトCXCL1アミノ酸配列上のエピトープの解析を行った。
実施例3より、配列番号1で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG2b-1と、配列番号3で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-10のビオチン標識体を用いたサンドイッチELISA法によるヒトCXCL1の測定を行った。IgG1-10のビオチン化はSulfo-NHS Biotin(PIERCE社製)を用いて行い、詳細は付属のプロトコールに従った。まず、IgG2b-1の10μg/mLのPBS溶液を調製した後、96ウェルポリスチレンプレート(グライナー社製)のウェルに100μLずつ入れ、一晩固相化した。翌日、前記溶液を廃棄し、1%BSA‐PBS溶液(SIGMA社製)を200μL注ぎ1時間室温で静置した。その後、PBS‐Tにて洗浄し、精製抗体固相化プレートとした。次に組換え型ヒトCXCL1を500pg/mL~7.8pg/mLまで1%BSA‐PBSを用いて段階希釈した抗原溶液を各ウェルに100μLずつ添加し、1時間室温で反応させた。次に、ウェル内の抗原溶液を廃棄してPBS‐Tにて洗浄した後、1%BSA-PBSを用いて希釈した1μg/mLビオチン標識IgG1-10 100μLを1時間室温で反応させた。洗浄後、avidin-HRP溶液(R&DSYSTEMS社製)100μLを30分間室温で反応させた。Avidin-HRPの希釈も1%BSA‐PBSを用いて行った。PBS-Tにて洗浄後、TMB溶液100μLを入れて15分反応させた後、2N硫酸溶液100μLを添加して反応を停止させ、450nmの吸光度を測定した。結果を図1に示す。
実施例3より、配列番号1で示されるアミノ酸配列領域を特異的に認識することが判明したモノクローナル抗体IgG2b-1と、配列番号3で示されるアミノ酸配列領域を特異的に認識することが判明したモノクローナル抗体IgG1-14のビオチン標識体を用いたサンドイッチELISA法によるヒトCXCL1の測定を行った。IgG1-14のビオチン化及びサンドイッチELISAについては実施例4と同様に実施した。結果を図1に示す。
実施例3より、配列番号2で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-3と、配列番号3で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-14のビオチン標識体を用いたサンドイッチELISA法によるヒトCXCL1の測定を行った。IgG1-14のビオチン化及びサンドイッチELISAについては実施例4と同様に実施した。結果を図1に示す。
市販のヒトCXCL1検出キットであるHuman CXCL1/GRO alpha DuoSet(R&DSYSTEMS社製)を用いて組換え型ヒトCXCL1の測定を行った。当該キットは、抗ヒトCXCL1マウスモノクローナル抗体(配列番号2で示されるアミノ酸配列を認識する。)を固相化し、検出はビオチン化標識ヤギポリクローナル抗体を用いるものである。固相化は、グライナー社製の96ウェルポリスチレンプレートに行い、詳細な実験操作は付属のプロトコールに従った。結果を図1、図4及び図5に示す。
実施例3より、配列番号1で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG2b-1と、配列番号3で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-10のビオチン標識体、又はIgG-10とIgG1-14をそれぞれビオチン標識したビオチン標識体の混合液を用いたサンドイッチELISA法によるヒトCXCL1の測定を行った。抗体のビオチン化及びサンドイッチELISAについては実施例4と同様に実施した。その結果を図2に示す。
実施例3より、配列番号1で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG2b-1と、配列番号3で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-10のビオチン標識体、又はIgG1-14のビオチン標識体を用いたサンドイッチELISA法による尿中に添加したヒトCXCL1の測定を行った。IgG1-10及びIgG1-14のビオチン化はSulfo-NHS Biotin(PIERCE社製)を用いて行い、詳細は付属のプロトコールに従った。まず、IgG2b-1の10μg/mLのPBS溶液を調製した後、96ウェルポリスチレンプレート(グライナー社製)のウェルに100μLずつ入れ、一晩固相化した。翌日、前記溶液を廃棄し、1%BSA-PBS溶液(SIGMA社製)を200μL注ぎ1時間室温で静置した。その後、PBS-Tにて洗浄し、精製抗体固相化プレートとした。次に組換え型ヒトCXCL1を当日採取したヒト尿に250pg/mLとなるように添加し、3.9pg/mLまで同ヒト尿を用いて段階希釈した抗原添加尿を各ウェルに100μLずつ添加し、1時間室温で反応させた。次に、ウェル内の抗原溶液を廃棄してPBS‐Tにて洗浄した後、1%BSA-PBSを用いて希釈した1μg/mLビオチン標識IgG1-10 100μLを1時間室温で反応させた。洗浄後、avidin-HRP溶液(R&DSYSTEMS社製)100μLを30分間室温で反応させた。Avidin-HRPの希釈も1%BSA-PBSを用いて行った。PBS-Tにて洗浄後、TMB溶液100μLを入れて15分反応させた後、2N硫酸溶液100μLを添加して反応を停止させ、450nmの吸光度を測定した。結果を図3に示す。
実施例3より、配列番号2で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-3と、配列番号3で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-14のビオチン標識体を用いたサンドイッチELISA法による尿中に添加したヒトCXCL1の測定を行った。抗体のビオチン化及びサンドイッチELISAについては実施例8と同様に実施した。結果を図3に示す。
市販のヒトCXCL1検出キットであるHuman CXCL1/GRO alpha DuoSet(R&DSYSTEMS社製)を用いて尿中に添加した組換え型ヒトCXCL1の測定を行った。詳細な実験操作は付属のプロトコールに従い、ヒト尿に添加したCXCL1溶液は実施例8と同様に調製した。結果を図3に示す。
実施例3において配列番号2で示されるアミノ酸配列領域を特異的に認識することが判明した市販キットHuman CXCL1/GRO alpha DuoSet(R&DSYSTEMS社製)付属のマウスモノクローナル抗体と、配列番号3で示されるアミノ酸配列領域を特異的に認識することが判明した抗体IgG1-10のビオチン標識体を用いて、サンドイッチELISA法による緩衝液に添加したヒトCXCL1の測定を行った。IgG1-10のビオチン化はSulfo-NHS Biotin(PIERCE社製)を用いて行い、詳細は付属のプロトコールに従った。まず、市販キット付属のマウスモノクローナル抗体の4μg/mLのPBS溶液を調製した後、96ウェルポリスチレンプレート(グライナー社製)のウェルに100μLずつ入れ、一晩固相化した。翌日、前記溶液を廃棄し、1%BSA-PBS溶液(SIGMA社製)を200μL注ぎ1時間室温で静置した。その後、PBS-Tにて洗浄し、精製抗体固相化プレートとした。次に組換え型ヒトCXCL1を500pg/mL~7.8pg/mLまで1%BSA‐PBSを用いて段階希釈した抗原溶液を各ウェルに100μLずつ添加し、1時間室温で反応させた。次に、ウェル内の抗原溶液を廃棄してPBS‐Tにて洗浄した後、1%BSA-PBSを用いて希釈した1μg/mLビオチン標識IgG1-10 100μLを1時間室温で反応させた。洗浄後、avidin-HRP溶液(R&DSYSTEMS社製)100μLを30分間室温で反応させた。Avidin-HRPの希釈も1%BSA-PBSを用いて行った。PBS-Tにて洗浄後、TMB溶液100μLを入れて15分反応させた後、2N硫酸溶液100μLを添加して反応を停止させ、450nmの吸光度を測定した。結果を図4に示す。
実施例2にて選抜した5種類の抗体IgG1-1、IgG1-3、IgG1-10、IgG1-14、IgG2b-1について、それぞれ10μg/mLのPBS溶液を調製した後、96ウェルポリスチレンプレート(グライナー社製)のウェルに100μLずつ入れ、一晩固相化した。翌日、前記溶液を廃棄し、1%BSA-PBS溶液(SIGMA社製)を200μL注ぎ1時間室温で静置した。その後、PBS-Tにて洗浄し、精製抗体固相化プレートとした。次に組換え型ヒトCXCL1タンパク質を125pg/mLから15pg/mLまで1%BSA-PBSを用いて段階希釈した抗原溶液を各ウェルに100μLずつ添加し、1時間室温で反応させた。次に、ウェル内の抗原溶液を廃棄してPBS-Tにて洗浄した後、1%BSA-PBSを用いて希釈した50ng/mLビオチン標識抗ヒトCXCL1ポリクローナル抗体(R&DSYSTEMS社製)100μLを1時間室温で反応させた。洗浄後、avidin‐HRP溶液(R&DSYSTEMS社製)100μLを30分間室温で反応させた。Avidin‐HRPの希釈も1%BSA-PBSを用いて行った。PBS-Tにて洗浄後、TMB溶液100μLを入れて15分反応させた後、2N硫酸溶液100μLを添加して反応を停止させ、450nmの吸光度を測定した。結果を図5に示す。
実施例2にて選抜した5種類の抗体IgG1‐1、IgG1‐3、IgG1‐10、IgG1‐14、IgG2b‐1を用いて、血漿に溶解したヒトCXCL1の検出を行った。
市販の抗ヒトCXCL1モノクローナル抗体であるMAB275(R&DSYSTEMS社製)を用いて、血漿に溶解したヒトCXCL1の検出を行った。PBSで希釈した10μg/mLのMAB275溶液を調製し、それぞれ100μLずつ96ウェルポリスチレンプレート(グライナー社製)のウェルに入れ、一晩固相化した。以降は実施例6と同様の方法で行った。結果を図6に示す。
実施例2にて選抜した5種類の抗体IgG1‐1、IgG1‐3、IgG1‐10、IgG1‐14、IgG2b‐1を用いて、尿に溶解したヒトCXCL1の検出を行った。
市販の抗ヒトCXCL1モノクローナル抗体であるMAB275(R&DSYSTEMS社製)を用いて、尿に溶解したヒトCXCL1の検出を行った。PBSで希釈した10μg/mLのMAB275溶液を調製し、それぞれ100μLずつ96ウェルポリスチレンプレート(グライナー社製)のウェルに入れ、一晩固相化した。以降は実施例13と同様の方法で行った。結果を図7に示す。
実施例2にて選抜した5種類の抗体IgG1-1、IgG1-3、IgG1-10、IgG1-14、IgG2b-1について、膀胱癌細胞の浸潤能を抑制する中和活性の測定を行った。
市販の抗ヒトCXCL1モノクローナル抗体であるMAB275(R&DSYSTEMS社製)について、膀胱癌細胞の浸潤能を抑制する中和活性の測定を行った。方法は実施例14と同様に行った。結果を図8に示す。
実施例2にて選抜した5種類の抗体のうち、IgG1-3、IgG1-10、IgG1-14、IgG2b-1の4種類について、膀胱癌細胞の浸潤能を抑制する中和活性の測定を行った。なお実施例14とは異なり、抗体を浸潤能測定の直前ではなく、前培養の段階から混合した。
市販の抗ヒトCXCL1モノクローナル抗体であるMAB275(R&DSYSTEMS社製)について、膀胱癌細胞の浸潤能を抑制する中和活性の測定を行った。比較例7とは異なり、抗体を浸潤能測定の直前ではなく、前培養の段階から混合した。方法は実施例15と同様に行った。結果を図9に示す。
Claims (15)
- ヒトCXCL1タンパク質を構成するアミノ酸配列の部分配列である配列番号1~3で示されるアミノ酸配列のいずれか1つの配列領域を特異的に認識し、かつそれぞれ異なる配列領域を特異的に認識する2種類以上の抗ヒトCXCL1モノクローナル抗体又はその断片を使用して、試料中のヒトCXCL1又はその断片を測定することを特徴とする、ヒトCXCL1タンパク質の免疫学的測定方法。
- 配列番号3で示されるアミノ酸配列領域を特異的に認識する抗ヒトCXCL1モノクローナル抗体又はその断片を使用して、試料中のヒトCXCL1タンパク質又はその断片を測定することを特徴とする、請求項1に記載のヒトCXCL1タンパク質の免疫学的測定方法。
- 配列番号1で示されるアミノ酸配列領域を特異的に認識する抗ヒトCXCL1モノクローナル抗体又はその断片及び配列番号3で示されるアミノ酸配列領域を特異的に認識する抗ヒトCXCL1モノクローナル抗体又はその断片を使用して、試料中のヒトCXCL1タンパク質又はその断片を測定することを特徴とする、請求項1又は2に記載のヒトCXCL1タンパク質の免疫学的測定方法。
- 配列番号2で示されるアミノ酸配列領域を特異的に認識する抗ヒトCXCL1モノクローナル抗体又はその断片及び配列番号3で示されるアミノ酸配列領域を特異的に認識する抗ヒトCXCL1モノクローナル抗体又はその断片を使用して、試料中のヒトCXCL1タンパク質又はその断片を測定することを特徴とする、請求項1又は2に記載のヒトCXCL1タンパク質の免疫学的測定方法。
- 前記試料が術後採取組織、血液、血清、血漿、尿、髄液、唾液、リンパ液、涙液又は精液である、請求項1~4のいずれかに記載のヒトCXCL1タンパク質の免疫学的測定方法。
- 前記配列番号3で示されるアミノ酸配列領域を特異的に認識し、
軽鎖において、
CDR1が配列番号4で示されるアミノ酸配列を含み、及び
CDR2が配列番号5で示されるアミノ酸配列を含み、及び
CDR3が配列番号6で示されるアミノ酸配列を含み、
重鎖において、
CDR1が配列番号7で示されるアミノ酸配列を含み、及び
CDR2が配列番号8で示されるアミノ酸配列を含み、及び
CDR3が配列番号9で示されるアミノ酸配列を含む、
抗ヒトCXCL1モノクローナル抗体又はその断片。 - 軽鎖可変領域に配列番号10で示されるアミノ酸配列を含み、重鎖可変領域に配列番号11で示されるアミノ酸配列を含む、請求項6に記載の抗ヒトCXCL1モノクローナル抗体又はその断片。
- 前記配列番号1で示されるアミノ酸配列領域を特異的に認識し、
軽鎖において、
CDR1が配列番号12で示されるアミノ酸配列を含み、及び
CDR2が配列番号13で示されるアミノ酸配列を含み、及び
CDR3が配列番号14で示されるアミノ酸配列を含み、
重鎖において、
CDR1が配列番号15で示されるアミノ酸配列を含み、及び
CDR2が配列番号16で示されるアミノ酸配列を含み、及び
CDR3が配列番号17で示されるアミノ酸配列を含む、
抗ヒトCXCL1モノクローナル抗体又はその断片。 - 軽鎖可変領域に配列番号18で示されるアミノ酸配列を含み、重鎖可変領域に配列番号19で示されるアミノ酸配列を含む、請求項8に記載の抗ヒトCXCL1モノクローナル抗体又はその断片。
- 前記配列番号3で示されるアミノ酸配列領域を特異的に認識し、
軽鎖において、
CDR1が配列番号20で示されるアミノ酸配列を含み、及び
CDR2が配列番号21で示されるアミノ酸配列を含み、及び
CDR3が配列番号22で示されるアミノ酸配列を含み、
重鎖において、
CDR1が配列番号23で示されるアミノ酸配列を含み、及び
CDR2が配列番号24で示されるアミノ酸配列を含み、及び
CDR3が配列番号25で示されるアミノ酸配列を含む、
抗ヒトCXCL1モノクローナル抗体又はその断片。 - 軽鎖可変領域に配列番号26で示されるアミノ酸配列を含み、重鎖可変領域に配列番号27で示されるアミノ酸配列を含む、請求項10に記載の抗ヒトCXCL1モノクローナル抗体又はその断片。
- 前記配列番号2で示されるアミノ酸配列領域を特異的に認識し、
軽鎖において、
CDR1が配列番号28で示されるアミノ酸配列を含み、及び
CDR2が配列番号29で示されるアミノ酸配列を含み、及び
CDR3が配列番号30で示されるアミノ酸配列を含み、
重鎖において、
CDR1が配列番号31で示されるアミノ酸配列を含み、及び
CDR2が配列番号32で示されるアミノ酸配列を含み、及び
CDR3が配列番号33で示されるアミノ酸配列を含む、
抗ヒトCXCL1モノクローナル抗体又はその断片。 - 軽鎖可変領域に配列番号34で示されるアミノ酸配列を含み、重鎖可変領域に配列番号35で示されるアミノ酸配列を含む、請求項12に記載の抗ヒトCXCL1モノクローナル抗体又はその断片。
- 前記配列番号3で示されるアミノ酸配列領域を特異的に認識し、
軽鎖において、
CDR1が配列番号36で示されるアミノ酸配列を含み、及び
CDR2が配列番号37で示されるアミノ酸配列を含み、及び
CDR3が配列番号38で示されるアミノ酸配列を含み、
重鎖において、
CDR1が配列番号39で示されるアミノ酸配列を含み、及び
CDR2が配列番号40で示されるアミノ酸配列を含み、及び
CDR3、が配列番号41で示されるアミノ酸配列を含む、
抗ヒトCXCL1モノクローナル抗体又はその断片。 - 軽鎖可変領域に配列番号42で示されるアミノ酸配列を含み、重鎖可変領域に配列番号43で示されるアミノ酸配列を含む、請求項14に記載の抗ヒトCXCL1モノクローナル抗体又はその断片。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2011121818/10A RU2521669C2 (ru) | 2008-10-31 | 2009-10-29 | Способ иммунологического анализа белка cxcl1 человека |
EP09823664.9A EP2363471B1 (en) | 2008-10-31 | 2009-10-29 | Immunoassay method for human cxcl1 protein |
CN2009801495634A CN102245767B (zh) | 2008-10-31 | 2009-10-29 | 人cxcl1蛋白质的免疫学测定方法 |
JP2010500582A JP5941615B2 (ja) | 2008-10-31 | 2009-10-29 | ヒトcxcl1タンパク質の免疫学的測定方法 |
US13/126,877 US9309312B2 (en) | 2008-10-31 | 2009-10-29 | Immunoassay method for human CXCL1 protein |
KR1020117012329A KR101682257B1 (ko) | 2008-10-31 | 2009-10-29 | 인간 cxcl1 단백질의 면역학적 측정 방법 |
CA2742157A CA2742157A1 (en) | 2008-10-31 | 2009-10-29 | Immunoassay method for human cxcl1 protein |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-281908 | 2008-10-31 | ||
JP2008281908 | 2008-10-31 | ||
JP2009039411 | 2009-02-23 | ||
JP2009-039411 | 2009-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010050554A1 true WO2010050554A1 (ja) | 2010-05-06 |
Family
ID=42128913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/068587 WO2010050554A1 (ja) | 2008-10-31 | 2009-10-29 | ヒトcxcl1タンパク質の免疫学的測定方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9309312B2 (ja) |
EP (1) | EP2363471B1 (ja) |
JP (1) | JP5941615B2 (ja) |
KR (1) | KR101682257B1 (ja) |
CN (4) | CN103408663B (ja) |
CA (1) | CA2742157A1 (ja) |
RU (1) | RU2521669C2 (ja) |
WO (1) | WO2010050554A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015529641A (ja) * | 2012-07-13 | 2015-10-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Rspo3結合剤およびその使用法 |
JP2016060743A (ja) * | 2014-09-17 | 2016-04-25 | 大韓民国 国立水産科学院Republic Of Korea(National Fisheries Research And Development Institute) | 日本ウナギの一本鎖の卵胞刺激ホルモンポリペプチド、これに対する抗体及びこれらの用途 |
US10064937B2 (en) | 2014-09-16 | 2018-09-04 | Oncomed Pharmaceuticals, Inc. | Treatment of dermal fibrosis |
EP3917949A4 (en) * | 2019-01-28 | 2022-11-23 | Charles J. Rosser | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO CXCL1 FUNCTION |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2173379B2 (en) | 2007-07-02 | 2023-07-05 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
AU2012284254B2 (en) | 2011-07-15 | 2015-07-09 | Oncomed Pharmaceuticals, Inc. | RSPO binding agents and uses thereof |
CL2015002152A1 (es) | 2015-07-31 | 2016-06-03 | Pontificia Universidad Católica De Chile | Anticuerpos monoclonales específicos para el antígeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnostico de la infección causada por vrsh |
MX2018011244A (es) * | 2016-03-16 | 2019-05-30 | Abeome Corp | Anticuerpos monoclonales neutralizantes para il-25 y usos de estos. |
EP3573651A4 (en) | 2017-01-27 | 2020-10-14 | NGM Biopharmaceuticals, Inc. | GLUCAGON RECEPTOR BINDING PROTEINS AND METHODS OF USE |
WO2019055776A2 (en) * | 2017-09-14 | 2019-03-21 | Rosser Charles | COMPOSITIONS AND METHODS FOR TREATING DISEASES INVOLVING CXCL1 FUNCTION |
US10961315B2 (en) | 2018-07-27 | 2021-03-30 | Ngm Biopharmaceuticals, Inc. | Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody |
JP7366411B2 (ja) * | 2020-01-23 | 2023-10-23 | 国立大学法人北海道大学 | ヒトαディフェンシンHD5を検出する方法及びキット、並びにこれらにおいて用いられる抗体 |
CN113186284B (zh) * | 2021-05-06 | 2022-01-07 | 浙江东方基因生物制品股份有限公司 | 一种核酸-抗体双重癌症检测试剂盒 |
CN113249445B (zh) * | 2021-05-28 | 2022-01-04 | 杭州康佰裕医学检验实验室有限公司 | 核酸-抗体双重癌症检测试剂盒 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
WO1997013844A1 (en) | 1995-10-06 | 1997-04-17 | Cambridge Antibody Technology Limited | Specific binding members for human transforming growth factor beta; materials and methods |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
JPH1054830A (ja) | 1996-08-12 | 1998-02-24 | Omomo Souuemon | テストストリップの製造システム |
WO2007026895A1 (ja) | 2005-09-02 | 2007-03-08 | Toray Industries, Inc. | 尿路上皮ガンの検出用キットおよび方法 |
WO2008013257A1 (fr) * | 2006-07-28 | 2008-01-31 | Shionogi & Co., Ltd. | Anticorps monoclonal dirigé contre le lox-1 soluble |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5501969A (en) * | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
AU757961B2 (en) * | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
AU2003291549A1 (en) * | 2002-11-15 | 2004-06-15 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
WO2006074430A2 (en) * | 2005-01-07 | 2006-07-13 | The Johins Hopkins University | Biomarkers for melanoma |
WO2007086915A2 (en) * | 2005-05-12 | 2007-08-02 | Applied Genomics, Inc. | Reagents and methods for use in cancer diagnosis, classification and therapy |
UA16041U (en) * | 2006-02-16 | 2006-07-17 | Vitrotestoe Scient And Product | A set of monoclonal antibodies of p2, p3, p4, p5, p6, specific to protein of p24 human immunodeficiency virus, suitable for use in immuno fermentative analysis |
US7598028B2 (en) | 2006-11-28 | 2009-10-06 | The Regents Of The University Of Michigan | Compositions and methods for detecting and treating prostate disorders |
CN101290318B (zh) | 2007-04-17 | 2012-08-08 | 上海市肿瘤研究所 | 一种用于诊断肝癌的elisa试剂盒 |
-
2009
- 2009-10-29 JP JP2010500582A patent/JP5941615B2/ja not_active Expired - Fee Related
- 2009-10-29 KR KR1020117012329A patent/KR101682257B1/ko active IP Right Grant
- 2009-10-29 CN CN201310360511.XA patent/CN103408663B/zh not_active Expired - Fee Related
- 2009-10-29 CN CN2009801495634A patent/CN102245767B/zh not_active Expired - Fee Related
- 2009-10-29 EP EP09823664.9A patent/EP2363471B1/en not_active Not-in-force
- 2009-10-29 RU RU2011121818/10A patent/RU2521669C2/ru not_active IP Right Cessation
- 2009-10-29 CN CN201310360469.1A patent/CN103483450B/zh not_active Expired - Fee Related
- 2009-10-29 US US13/126,877 patent/US9309312B2/en not_active Expired - Fee Related
- 2009-10-29 CA CA2742157A patent/CA2742157A1/en not_active Abandoned
- 2009-10-29 WO PCT/JP2009/068587 patent/WO2010050554A1/ja active Application Filing
- 2009-10-29 CN CN201310360533.6A patent/CN103408664B/zh not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002809A1 (en) | 1988-09-02 | 1990-03-22 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US6350861B1 (en) | 1992-03-09 | 2002-02-26 | Protein Design Labs, Inc. | Antibodies with increased binding affinity |
WO1997013844A1 (en) | 1995-10-06 | 1997-04-17 | Cambridge Antibody Technology Limited | Specific binding members for human transforming growth factor beta; materials and methods |
JPH1054830A (ja) | 1996-08-12 | 1998-02-24 | Omomo Souuemon | テストストリップの製造システム |
WO2007026895A1 (ja) | 2005-09-02 | 2007-03-08 | Toray Industries, Inc. | 尿路上皮ガンの検出用キットおよび方法 |
WO2008013257A1 (fr) * | 2006-07-28 | 2008-01-31 | Shionogi & Co., Ltd. | Anticorps monoclonal dirigé contre le lox-1 soluble |
Non-Patent Citations (33)
Title |
---|
"Clinical Pathology Extra Special Edition No. 53, Immunoassay for Clinical Examination - Technology and Application", 1983, THE CLINICAL PATHOLOGY PRESS |
"Fundamental Immunology", 1993 |
"Pierce catalog and Handbook", 1994, PIERCE CHEMICAL CO. |
"Protein Nucleic Acid Enzyme Separate Volume No. 31 Enzyme Immunoassay", 1987, KYORITSU SHUPPAN CO., LTD |
"Radioimmunoassay Part II", 1979, KODANSHA SCIENTIFIC LTD. |
"Radioimmunoassay", 1974, KODANSHA SCIENTIFIC LTD. |
BRINKMANN ET AL., J IMMUNOL METHODS, vol. 182, 1995, pages 41 - 50 |
CANCER RESEARCH, vol. 50, 1990, pages 1495 - 1502 |
E. A. KABAT ET AL.: "Sequences of proteins of immunological interest", vol. 1, 1991, NIH PUBLICATION |
EIJI ISHIKAWA ET AL.: "Enzyme Immunoassay", 1987, IGAKU-SHOIN |
EUROPEAN JOURNAL OF CANCER RESEARCH PREVIEW, vol. 5, 1996, pages 512 - 519 |
GONG YANG ET AL., PNAS, vol. 103, no. 44, 2006, pages 16472 - 16477 |
HAJIME KARASUYAMA: "Experimental Medicine Separate Volume: Genetic Engineering Handbook", 1991, YODOSHA, article "Bovine Papilloma Virus Vector", pages: 297 - 299 |
HIROAKI KAWANISHI ET AL., CLINICAL CANCER RESEARCH, vol. 14, no. 9, 2008, pages 2579 - 2587 |
HOLLIGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448 |
JING LUAN ET AL., JOURNAL OF LEUKOCYTE BIOLOGY, vol. 62, no. 5, 1997, pages 588 - 597 |
JOURNAL OF IMMUNOLOGY, vol. 160, 1998, pages 3393 - 3402 |
KAWANISHI H. ET AL.: "Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer.", CLIN. CANCER. RES., vol. 14, no. 9, May 2008 (2008-05-01), pages 2579 - 2587, XP008149803 * |
KAZUHIRO NAGATA, HIROSHI HANDA: "Experimental Method for Realtime Analysis of Biomaterial Interaction", 2000, SPRINGER-VERLAG |
KUBY, J.: "Immunology", 1998, W. H. FREEMAN & CO. |
MARVIN ET AL., ACTA PHARMACOL. SIN., vol. 26, 2005, pages 649 - 658 |
MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 522 - 554 |
NATURE, vol. 266, 1977, pages 550 - 552 |
NATURE, vol. 321, 1986, pages 522 |
OLAFSEN ET AL., PROT. ENGR. DES. SEL., vol. 17, 2004, pages 21 - 27 |
PNAS, vol. 84, 1987, pages 7413 |
PNAS, vol. 86, 1989, pages 6077 |
SAMBROOK, J. ET AL.: "Molecular Cloning: A Laboratory Manual Second", 1989, COLD SPRING HARBOR LABORATORY PRESS |
See also references of EP2363471A4 * |
VIROLOGY, vol. 52, 1973, pages 456 - 467 |
WEN Y. ET AL.: "GROalpha is highly expressed in adenocarcinoma of the colon and down-regulates fibulin-1.", CLIN. CANCER. RES., vol. 12, no. 20, 2006, pages 5951 - 5959, XP008149807 * |
YANG G. ET AL.: "The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.", PROC. NATL. ACAD. SCI. USA., vol. 103, no. 44, 2006, pages 16472 - 16477, XP008149819 * |
YU WEN ET AL., CLINICAL CANCER RESEARCH, vol. 12, no. 20, 2006, pages 5951 - 5959 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015529641A (ja) * | 2012-07-13 | 2015-10-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Rspo3結合剤およびその使用法 |
US10064937B2 (en) | 2014-09-16 | 2018-09-04 | Oncomed Pharmaceuticals, Inc. | Treatment of dermal fibrosis |
JP2016060743A (ja) * | 2014-09-17 | 2016-04-25 | 大韓民国 国立水産科学院Republic Of Korea(National Fisheries Research And Development Institute) | 日本ウナギの一本鎖の卵胞刺激ホルモンポリペプチド、これに対する抗体及びこれらの用途 |
EP3917949A4 (en) * | 2019-01-28 | 2022-11-23 | Charles J. Rosser | COMPOSITIONS AND METHODS FOR TREATMENT OF DISORDERS RELATED TO CXCL1 FUNCTION |
US11760796B2 (en) | 2019-01-28 | 2023-09-19 | Charles J. Rosser | Compositions and methods for treatment of diseases involving CXCL1 function |
Also Published As
Publication number | Publication date |
---|---|
CN103483450B (zh) | 2015-11-25 |
EP2363471B1 (en) | 2016-10-12 |
RU2011121818A (ru) | 2012-12-10 |
KR101682257B1 (ko) | 2016-12-05 |
CN102245767B (zh) | 2013-09-18 |
CN103483450A (zh) | 2014-01-01 |
KR20110090985A (ko) | 2011-08-10 |
JP5941615B2 (ja) | 2016-06-29 |
CN103408663B (zh) | 2016-01-27 |
EP2363471A1 (en) | 2011-09-07 |
CN102245767A (zh) | 2011-11-16 |
US20110287444A1 (en) | 2011-11-24 |
CN103408664B (zh) | 2015-11-25 |
US9309312B2 (en) | 2016-04-12 |
RU2521669C2 (ru) | 2014-07-10 |
JPWO2010050554A1 (ja) | 2012-03-29 |
EP2363471A4 (en) | 2013-10-30 |
CN103408663A (zh) | 2013-11-27 |
CN103408664A (zh) | 2013-11-27 |
CA2742157A1 (en) | 2010-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5941615B2 (ja) | ヒトcxcl1タンパク質の免疫学的測定方法 | |
US9823251B2 (en) | Anti-Uroplakin II antibodies systems and methods | |
KR20160065876A (ko) | 췌장 종양의 검출 방법, 항체 및 췌장 종양 검출용 키트 | |
CN109336973B (zh) | 抗转铁蛋白抗体及其用途 | |
KR101138460B1 (ko) | 항-fasn 자가면역 항체를 포함하는 간암 진단 마커 및 이의 항원을 포함하는 간암 진단용 조성물 | |
WO2016121695A1 (ja) | 胆道癌の検出方法及び胆道癌検出用キット | |
WO2013015367A1 (ja) | 上皮性卵巣癌マーカー検出用抗体及び上皮性卵巣癌判定方法 | |
US11174310B2 (en) | Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement | |
JP5770092B2 (ja) | ヒトhig1ポリペプチドに対するモノクローナル抗体 | |
US9127054B2 (en) | Immunoassay of cofilin 1 protein | |
WO2022202826A1 (ja) | 悪性膵嚢胞性腫瘍の判定補助方法及び判定補助用キット | |
EP2957571B1 (en) | Monoclonal anti-pvhl antibodies and uses thereof | |
JPWO2009022632A1 (ja) | 新規肝癌マーカー | |
KR100996486B1 (ko) | 인체 무등(mudeng) 단백질에 대한 단일클론 항체 | |
CN116234823A (zh) | 用于在免疫组织化学(ihc)方案中诊断癌症的抗体 | |
JP2012070648A (ja) | マウスhig1ポリペプチドに対するモノクローナル抗体 | |
JPWO2003052102A1 (ja) | ブラディオン検出用特異的抗体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980149563.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010500582 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09823664 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2742157 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13126877 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2044/KOLNP/2011 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2009823664 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009823664 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117012329 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011121818 Country of ref document: RU |